

# CITATION REPORT

List of articles citing

## Erlotinib in previously treated non-small-cell lung cancer

DOI: 10.1056/nejmoa050753

New England Journal of Medicine, 2005, 353, 123-32.

**Source:** <https://exaly.com/paper-pdf/39504675/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2188	.		
2187	Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment. <b>2010</b> , 4, 178		12
2186	Palliative systemic antineoplastic therapy. <b>2001</b> , 399-420		
2185	Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. <b>2005</b> , 128, 3975-84		88
2184	Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. <b>2005</b> , 70, 419-26		91
2183	Evolving molecular-based targeted therapy for cancer: an exciting field. <b>2005</b> , 31, 299-305		
2182	Trial design for testing new therapies in ovarian cancer. <b>2005</b> , 15 Suppl 3, 258-65		4
2181	HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. <b>2005</b> , 93, 1334-40		70
2180	An update on the role of epidermal growth factor receptor inhibitors in non-small cell lung cancer. <b>2005</b> , 32, S3-8		79
2179	Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. <b>2005</b> , 32, S9-15		69
2178	Preclinical data with bortezomib in lung cancer. <b>2005</b> , 7 Suppl 2, S49-55		23
2177	Bortezomib-based combinations in the treatment of non-small-cell lung cancer. <b>2005</b> , 7 Suppl 2, S59-63		8
2176	[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer]. <b>2005</b> , 100, 785-93		2
2175	Zukünftige klinische Entwicklung von Bevacizumab und Erlotinib. <b>2005</b> , 11, 49-52		
2174	Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?. <b>2005</b> , 23, 6813-6		54
2173	High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. <b>2005</b> , 65, 11478-85		124
2172	Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. <b>2005</b> , 60, 925-31		1109

2171	Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?. <b>2005</b> , 23, 9044-7		25
2170	How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care. <b>2005</b> , 10 Suppl 2, 23-9		20
2169	Adjuvant chemotherapy for non-small cell lung cancer: the new standard of care. <b>2005</b> , 1, 619-23		3
2168	Erlotinib in lung cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1739-41; author reply 1739-41	59.2	29
2167	Targeting EGFR in non-small-cell lung cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 200-2	59.2	30
2166	Erlotinib in the treatment of non-small cell lung cancer. <b>2005</b> , 5, 767-75		18
2165	[Therapy of lung cancer]. <b>2005</b> , 59, 783-97; quiz 798-803		1
2164	EGFR inhibitors: what have we learned from the treatment of lung cancer?. <b>2005</b> , 2, 554-61		69
2163	Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <b>2005</b> , 11, 8418-24		201
2162	Molecularly-targeted therapies for non-small cell lung cancer. <b>2005</b> , 6, 2667-79		5
2161	Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. <b>2005</b> , 23, 7738-40		32
2160	Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. <b>2006</b> , 61, 91		55
2159	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. <b>2005</b> , 11, 8288-94		193
2158	Bexarotene and erlotinib for aerodigestive tract cancer. <b>2005</b> , 23, 8757-64		58
2157	Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. <b>2005</b> , 23, 9265-74		122
2156	Receptor tyrosine kinase mutations: molecular indicators for therapeutic response or signposts marking important signaling pathways?. <b>2005</b> , 4, 1417-8		
2155	Biomarkers to predict response to epidermal growth factor receptor inhibitors. <b>2005</b> , 4, 1369-72		63
2154	Molecular targeted therapy for lung cancer. <b>2005</b> , 366, 1507-8		7

2153	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). <b>2005</b> , 366, 1527-37		1802
2152	Optimizing chemotherapy and targeted agent combinations in NSCLC. <b>2005</b> , 50, S25-S32		17
2151	Targeted therapy for non-small cell lung cancer. <b>2005</b> , 17, 199-204		8
2150	Erlotinib in lung cancer - molecular and clinical predictors of outcome. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 133-44	59.2	1594
2149	An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer. <b>2005</b> , 6, 2855-66		8
2148	Tyrosine kinases as targets for cancer therapy. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 172-87	59.2	1084
2147	Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. <b>2005</b> , 27, 1513-34		82
2146	Resistance to epidermal growth factor receptor-targeted therapy. <b>2005</b> , 8, 298-310		66
2145	Erlotinib. <b>2005</b> , 4, 247-252		3
2144	Erlotinib. <b>2005</b> , 4, 253-254		1
2143	Erlotinib. <b>2005</b> , 4, 253-254		1
2142	Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. <b>2006</b> , 3, 448-57		552
2141	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. <b>2006</b> , 95, 998-1004		244
2140	Forthcoming receptor tyrosine kinase inhibitors. <b>2006</b> , 10, 793-7		4
2139	Taxanes in the treatment of non-small cell lung cancer. <b>2006</b> , 5, 181-91		5
2138	Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer. <b>2006</b> , 5, 223-244		2
2137	Les critères d'évaluation des cancers broncho-pulmonaires. <b>2006</b> , 23, 112-117		
2136	The place of targeted therapies in the management of non-small cell bronchial carcinoma. <b>2006</b> , 23, 137-147		2

2135	Epidermal growth factor receptor status in anaplastic thyroid carcinoma. <b>2007</b> , 60, 881-4	31
2134	De lâASCO 2006 ^ la pratique courante. <b>2006</b> , 62, 27-33	
2133	Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. <b>2006</b> , 95, 1070-5	41
2132	Pharmacodynamic biomarkers for molecular cancer therapeutics. <b>2007</b> , 96, 213-68	124
2131	Erlotinib: profile report. <b>2006</b> , 22, 1-2	
2130	Epidermal growth factor receptor as a major anticancer drug target. <b>2006</b> , 10, 877-88	6
2129	Should every lung cancer patient be tested for EGFR mutation?. <b>2006</b> , 10, 789-91	1
2128	Is EGFR expression important in non-small cell lung cancer?. <b>2006</b> , 61, 98-9	33
2127	PC-FACS: a real-time evidence resource for busy palliative care clinicians. <b>2006</b> , 9, 24-8	3
2126	The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer. <b>2006</b> , 6, 531-44	13
2125	An�sis farmacoecon�mico del tratamiento con erlotinib, docetaxel, pemetrexed o tratamiento de soporte de pacientes con c�ncer de pulm�n no microc�fico avanzado, previamente tratado con quimioterapia. <b>2006</b> , 3, 137-149	3
2124	The wind of change in the therapy of lung cancer. <b>2006</b> , 6, 469-72	
2123	Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. <b>2006</b> , 11, 274-84	78
2122	Pemetrexed in thoracic cancer. <b>2006</b> , 7, 917-28	1
2121	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. <b>2006</b> , 24, 5034-42	623
2120	Comparative pharmacogenomics of antiretroviral and cytotoxic treatments. <b>2006</b> , 7, 61-8	9
2119	Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. <b>2006</b> , 7, 416-24	42
2118	Where next for gefitinib in patients with lung cancer?. <b>2006</b> , 7, 499-507	101

2117	A better crystal ball to predict lung-cancer survival?. <b>2006</b> , 7, 789-90	4
2116	C?ncer de pulm?n (II). Tratamiento m?dico. <b>2006</b> , 9, 4265-4269	
2115	Gefitinib for refractory advanced non-small-cell lung cancer. <b>2006</b> , 367, 300	0
2114	Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. <b>2006</b> , 5, 1799-810	168
2113	CBNPC stade IV: Dur?e optimale de la chimioth?rapie initiale des cancers non ^petites cellules localement avanc?s. <b>2006</b> , 23, 72-77	
2112	De l'ASCO et du WCLC 2005 ^ la pratique clinique : th?rapeutiques cibl?s. <b>2006</b> , 62, 30-34	
2111	Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. <b>2006</b> , 29, 1711	30
2110	Recent advances in the treatment of malignant astrocytoma. <b>2006</b> , 24, 1253-65	258
2109	[Lung cancer--the unhappy consequences of equality]. <b>2006</b> , 23, 115-6	0
2108	Targeting tyrosine kinases in cancer: the second wave. <b>2006</b> , 312, 1175-8	380
2107	Est-il n?cessaire de s?lectionner les patients pour prescrire des th?rapeutiques cibl?s dans les cancers bronchiques non ^petites cellules de stade IV ?. <b>2006</b> , 62, 41-44	
2106	Clinical trials in a molecular world. <b>2006</b> , 16, 681-94, ix	3
2105	Novel therapies targeting signaling pathways in lung cancer. <b>2006</b> , 16, 379-96, vi	10
2104	La place des th?rapeutiques cibl?s dans la prise en charge des CBNPC. <b>2006</b> , 23, 148-157	
2103	Novel targeted therapies for non-small cell lung cancer. <b>2006</b> , 16, 353-66	1
2102	The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer. <b>2006</b> , 23, 131-136	5
2101	Th?rapies cibl?s et´ immunomodulation dans´ les´ tumeurs solides. <b>2006</b> , 15, 297-302	
2100	CBNPC stade IV. <b>2006</b> , 23, 78-83	1

2099 Prise en charge du cancer du poumon chez les patients  $\bar{u}$ . **2006**, 62, 5-7

2098 Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. **2006**, 66, 1441-63 11

2097 Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. **2006**, 6, 59-65 9

2096 Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. **2006**, 6, 208-13 15

2095 Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. **2006**, 7, 385-8 112

2094 Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy. **2006**, 8, 99-109 6

2093 Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. **2006**, 8, 195-202 33

2092 Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. **2006**, 7 Suppl 4, S111-7 25

2091 Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. **2006**, 7 Suppl 4, S118-25 14

2090 Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. **2006**, 7 Suppl 4, S138-44 61

2089 Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. **2006**, 8 Suppl 1, S31-5 22

2088 Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. **2006**, 1, 19 97

2087 Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. **2006**, 24, 2158-63 127

2086 A review of erlotinib and its clinical use. **2006**, 7, 177-93 53

2085 Changing the course of oncogenesis: The development of tyrosine kinase inhibitors. **2006**, 4, 14-20 2

2084 The ISEL and BR21 trials â€œOutcomes similar or different?. **2006**, 4, 23-24 2

2083 A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. **2006**, 51, 115-21 27

2082 Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics. **2006**, 51, 137-8 3

2081	Second-line treatment for advanced non-small cell lung cancer: a systematic review. <b>2006</b> , 51, 159-72	41
2080	Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. <b>2006</b> , 52, 99-103	20
2079	A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. <b>2006</b> , 52, 333-8	8
2078	Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. <b>2006</b> , 52, 373	2
2077	Peptide ligands targeting integrin alpha3beta1 in non-small cell lung cancer. <b>2006</b> , 52, 291-7	28
2076	Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. <b>2006</b> , 53, 339-45	15
2075	A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. <b>2006</b> , 54, 69-77	33
2074	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. <b>2006</b> , 54, 201-7	31
2073	Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. <b>2006</b> , 54, 193-9	32
2072	Integrating new targeted agents into the treatment of non-small-cell lung cancer. <b>2006</b> , 54 Suppl 2, S25-31	5
2071	Second-line therapeutic options in non-small-cell lung cancer. <b>2006</b> , 54 Suppl 2, S15-8	4
2070	Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. <b>2006</b> , 66, 944-50	446
2069	Satraplatin: an orally available platinum analog for the treatment of cancer. <b>2006</b> , 6, 973-82	69
2068	Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer?. <b>2006</b> , 12, 5919-20	2
2067	Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. <b>2006</b> , 12, 4283-7	142
2066	Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. <b>2006</b> , 10, 306-15	34
2065	Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. <b>2006</b> , 32, 74-89	137
2064	Commentary: concomitant chemotherapy and radiation for limited stage small cell lung cancer and benefit of adding additional drug into chemotherapy regimen for advanced non-small cell lung cancer. <b>2006</b> , 32, 656-7	



2063	Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?. <b>2006</b> , 32, 630-6	26
2062	Targeted kinase inhibitors in lung cancer: from EGFR to patients. <b>2006</b> , 42, 124-5	
2061	Thérapeutiques anticancéreuses ciblées. <b>2006</b> , 27, S285-S288	2
2060	[Epidermal growth factor receptor inhibitors side effects]. <b>2006</b> , 97, 296-310	21
2059	EGFR-targeted therapy and related skin toxicity. <b>2006</b> , 22, 152-62	14
2058	Lung cancer. <b>2006</b> , 1, 235-272	1
2057	Epidermal growth factor receptor pathway inhibitors. <b>2006</b> , 1, 299-310	5
2056	Drugs for Lung Cancer Treatment. <b>2006</b> , 60, 123	
2055	Pharmacy benefit spending on oral chemotherapy drugs. <b>2006</b> , 12, 570-7	15
2054	Targeted therapies in solid tumors: Monoclonal antibodies and small molecules. <b>2006</b> , 15, 103-111	12
2053	Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. <b>2006</b> , 12, 472-8	30
2052	Epidermal growth factor receptor-targeted agents for lung cancer. <b>2006</b> , 13, 129-40	16
2051	Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. <b>2006</b> , 1, 847-855	101
2050	FARMACOGENTICA APLICADA AO CANCER. QUIMIOTERAPIA INDIVIDUALIZADA E ESPECIFICIDADE MOLECULAR. <b>2006</b> , 39, 577	1
2049	Erloiniib Nel Trattamento del NSCLC: Attualit�e Nuove Prospettive DALL'ASCO 2006. <b>2006</b> , 92, 13-22	
2048	The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. <b>2006</b> , 107, 4039-46	127
2047	In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib. <b>2006</b> , 397, 537-43	13
2046	Novel non-cytotoxic therapy in ovarian cancer: current status and future prospects. <b>2006</b> , 4, 955-66	14

2045	EGFR: A Prognostic and/or a Predictive Marker?. <b>2006</b> , 1, 395-397	4
2044	Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib. <b>2006</b> , 1, 837-846	32
2043	DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial. <b>2006</b> , 1, 984-990	27
2042	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. <b>2006</b> , 1, 367-376	24
2041	Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. <b>2006</b> , 1, 1042-1058	34
2040	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. <b>2006</b> , 1, 740-743	2
2039	Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer. <b>2006</b> , 1, 582-587	7
2038	A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. <b>2006</b> , 1, 1010-1019	1
2037	Toxicité des chimiothérapies en cancérologie pulmonaire. <b>2006</b> , 3, 1-21	1
2036	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. <b>2006</b> , 1, 52-60	
2035	Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib and Erlotinib in the Treatment of Non-small Cell Lung Cancer: A Systematic Review. <b>2006</b> , 1, 367-376	28
2034	Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. <b>2006</b> , 1, 847-855	140
2033	Immune-Modulating Vaccines in Non-small Cell Lung Cancer. <b>2006</b> , 1, 756-761	1
2032	Rational Development of Targeted Cancer Therapies Using Biomarkers. <b>2006</b> , 37, 482-489	
2031	Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. <b>2006</b> , 18, 135-43	30
2030	Bibliography. Current world literature. <b>2006</b> , 18, 671-709	
2029	Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy. <b>2006</b> , 1, 545-550	2
2028	Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib. <b>2006</b> , 1, 837-846	69

2027	Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. <b>2006</b> , 1, 180-187	19
2026	Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. <b>2006</b> , 1, 218-25	7
2025	EGFR: A Prognostic and/or a Predictive Marker?. <b>2006</b> , 1, 395-397	7
2024	Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. <b>2006</b> , 1, 1042-1058	64
2023	Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer. <b>2006</b> , 1, 740-743	4
2022	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. <b>2006</b> , 1, 965-971	11
2021	Erlotinib in-Previously Treated Non-Small-Cell Lung Cancer. <b>2006</b> , 2006, 231-233	1
2020	Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. <b>2006</b> , 1, 245-51	21
2019	DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter Trial. <b>2006</b> , 1, 984-990	30
2018	Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). <b>2006</b> , 1, 1-13	38
2017	New developments in chemotherapy for advanced non-small cell lung cancer. <b>2006</b> , 18, 156-61	8
2016	Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies). <b>2006</b> , 18, 307-15	9
2015	Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. <b>2006</b> , 18, 609-14	3
2014	Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIB or IV) non-small-cell lung cancer. <b>2006</b> , 17, 401-9	117
2013	Targeted therapies and non-small-cell lung cancer: work in progress?. <b>2006</b> , 18, 132-4	2
2012	Clinical experience with erlotinib in non-small-cell lung cancer. <b>2006</b> , 42, 147-56	15
2011	Epidermal growth factor receptor analyses in colorectal cancer: A comparison of methods. <b>2006</b> , 29, 1159	5
2010	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. <b>2006</b> , 83-132	1

2009	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. <b>2006</b> , 11, 687-92	27
2008	Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. <b>2006</b> , 11, 693-8	18
2007	Targeted cancer therapy: The prime time show in oncology. <b>2006</b> , 2, 1-2	
2006	Targeting epidermal growth factor receptor in lung cancer: Perspective from the Asiaâ€acific region. <b>2006</b> , 2, 22-31	1
2005	Erlotinib-associated skin reactions - case report and proposal for classification. <b>2006</b> , 155, 1293-5	3
2004	Recent trends in the treatment of advanced lung cancer. <b>2006</b> , 97, 448-52	16
2003	A critical appraisal of prognostic and predictive factors for common lung cancers. <b>2006</b> , 48, 779-86	18
2002	The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. <b>2006</b> , 24, 985-95	108
2001	Comparing antibody and small-molecule therapies for cancer. <b>2006</b> , 6, 714-27	531
2000	Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. <b>2006</b> , 94, 1136-43	114
1999	Vinflunine -- an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. <b>2006</b> , 94, 1383-8	48
1998	Clinical experience with gefitinib: an update. <b>2006</b> , 58, 31-45	46
1997	Proteasome inhibitors in lung cancer. <b>2006</b> , 58, 177-89	52
1996	Multitargeted therapy: can promiscuity be praised in an era of political correctness?. <b>2006</b> , 59, 150-8	24
1995	Kinase inhibitors in the treatment of renal cell carcinoma. <b>2006</b> , 60, 216-26	26
1994	Clinical trials assessing the optimal management of brain metastases--the state of play. <b>2006</b> , 18, 744-6	11
1993	Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. <b>2006</b> , 80, 136-45	169
1992	Present and future of lung cancer vaccines. <b>2006</b> , 11, 445-59	8

1991	Molekular zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms. <b>2006</b> , 12, 769-779	1
1990	Biological and clinical implications of EGFR mutations in lung cancer. <b>2006</b> , 11, 190-8	169
1989	Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer. <b>2006</b> , 58, 527-31	5
1988	Impact of EGFR mutations on treatment of non-small cell lung cancer. <b>2006</b> , 58, 5-9	3
1987	Clinical development of EGFR-tyrosine kinase inhibitors in Japan. <b>2006</b> , 58, 33-37	1
1986	[Requirements for the development of molecularly defined targeted therapy in oncology]. <b>2006</b> , 101, 617-23	1
1985	[Molecular targeted therapy]. <b>2006</b> , 77, 1118-25	3
1984	[Targeted therapy in the treatment of solid tumors and in hematology-oncology. Advances and disappointments]. <b>2006</b> , 47, 633-41	1
1983	New antiangiogenetic agents and non-small cell lung cancer. <b>2006</b> , 60, 76-86	19
1982	New target-based agents involve new clinical trial designs. <b>2006</b> , 8, 581-7	
1981	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. <b>2006</b> , 1, 23-33	1
1980	Erlotinib in a previously treated advanced non-small cell lung cancer elderly patient: a clinical case. <b>2006</b> , 1, 56-58	
1979	Targeted therapies in the treatment of advanced non-small cell lung cancer elderly patients. <b>2006</b> , 1, 13-22	1
1978	Advances in molecular diagnostics and therapeutics in head and neck cancer. <b>2006</b> , 7, 3-11	26
1977	Second- and third-line treatments in non-small cell lung cancer. <b>2006</b> , 7, 37-49	15
1976	Second-line Therapy for advanced non-small-cell lung cancer. <b>2006</b> , 8, 243-7	2
1975	New agents, new rashes: an update on skin complications from cancer chemotherapy. <b>2006</b> , 8, 269-74	3
1974	Erlotinib voor reeds behandelde niet-kleincellige longtumoren. <b>2006</b> , 44, 120-121	

1973	Bad patients meet good drugs. <b>2006</b> , 8, 225-7	1
1972	HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. <b>2006</b> , 10, 25-38	376
1971	Targeting ADAMS and ERBBs in lung cancer. <b>2006</b> , 10, 7-11	33
1970	Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. <b>2006</b> , 1766, 217-29	27
1969	2005 Highlights From: First Annual Lung Cancer Symposium, New York, NY, November 2005. <b>2006</b> , 7, 235-240	
1968	Respiratory medicine: anti-IgE therapy, lung cancer and pulmonary hypertension. <b>2006</b> , 34, 431-434	1
1967	Geographic variation in the second-line treatment of non-small cell lung cancer. <b>2006</b> , 33, S39-44	6
1966	Second-line treatment options in non-small cell lung cancer: a comparison of cytotoxic agents and targeted therapies. <b>2006</b> , 33, S17-24	7
1965	Optimizing therapy in previously treated non-small cell lung cancer. <b>2006</b> , 33, S25-31	7
1964	Second-line treatment options in advanced non-small cell lung cancer: current status. <b>2006</b> , 33, S3-8	7
1963	Epidermal growth factor receptor targeting in cancer. <b>2006</b> , 33, 369-85	560
1962	Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. <b>2006</b> , 26, 641-54	26
1961	Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer. <b>2006</b> , 7, 241-9	57
1960	Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. <b>2006</b> , 7, 250-6	68
1959	Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. <b>2006</b> , 7, 326-31	27
1958	Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. <b>2006</b> , 7, 389-94	140
1957	K-ras mutations in non-small-cell lung carcinoma: a review. <b>2006</b> , 8, 30-8	180
1956	A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer. <b>2006</b> , 8, 49-55	8

1955	Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology. <b>2006</b> , 8, 214-6	11
1954	The way forward: new drugs and new therapeutic strategies in lung cancer therapy. <b>2006</b> , 7 Suppl 4, S109-10	
1953	Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. <b>2006</b> , 8 Suppl 1, S7-14	78
1952	Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. <b>2006</b> , 8 Suppl 1, S15-22	12
1951	Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. <b>2006</b> , 7, 289	52
1950	Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. <b>2006</b> , 106, 2208-17	51
1949	A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. <b>2006</b> , 107, 781-92	91
1948	A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IV NSCLC previously treated with nonplatinum-based chemotherapy. <b>2006</b> , 107, 799-805	7
1947	A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. <b>2006</b> , 107, 1034-41	69
1946	Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. <b>2006</b> , 107, 1207-18	153
1945	Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. <b>2006</b> , 119, 727-34	16
1944	Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. <b>2006</b> , 5, 145-9	44
1943	EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. <b>2006</b> , 3, 170-1	16
1942	C-fos assessment as a marker of anti-epidermal growth factor receptor effect. <b>2006</b> , 66, 2385-90	28
1941	Her2-targeted therapies in non-small cell lung cancer. <b>2006</b> , 12, 4377s-4383s	54
1940	Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?. <b>2006</b> , 6, 165-73	4
1939	Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. <b>2006</b> , 17, 981-5	101
1938	Clinical Year in Review III: Critical care, mechanical ventilation, sleep medicine, and lung cancer. <b>2006</b> , 3, 645-9	1

1937	Point mutations of protein kinases and individualised cancer therapy. <b>2006</b> , 7, 2243-61	23
1936	The second annual symposium on the future of lung cancer: a translational focus. 11-12 November 2005, Washington D.C., USA. <b>2006</b> , 10, 475-80	
1935	Expression biomarkers for clinical efficacy and outcome prediction in cancer. <b>2006</b> , 7, 105-15	10
1934	Recent Clinical Trials in Non-Small Cell Lung Cancer. <b>2006</b> , 2, 81-99	
1933	Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel?. <b>2006</b> , 3, 294-5	2
1932	Tumorspezifische Therapien auch auf der Palliativstation? - Eine alte Frage neu beleuchtet. <b>2006</b> , 7, 19-24	1
1931	[New agents for solid tumours]. <b>2006</b> , 131, 2407-10	
1930	An in vivo platform for translational drug development in pancreatic cancer. <b>2006</b> , 12, 4652-61	364
1929	Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. <b>2006</b> , 12, 6049-55	173
1928	Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. <b>2006</b> , 12, 4436s-4440s	29
1927	A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. <b>2006</b> , 12, 3381-8	101
1926	Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. <b>2006</b> , 12, 3661-97	235
1925	Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. <b>2006</b> , 24, 1807-13	134
1924	Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. <b>2006</b> , 24, 2659-65	131
1923	Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. <b>2006</b> , 4, 521-8	119
1922	Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. <b>2006</b> , 12, 3078-84	85
1921	A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. <b>2006</b> , 12, 4274-82	28
1920	Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway. <b>2006</b> , 12, 7222-31	75



1919	Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. <b>2006</b> , 5, 2051-9	106
1918	Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. <b>2006</b> , 24, 4848-54	28
1917	Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. <b>2006</b> , 11, 655-65	42
1916	Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. <b>2006</b> , 12, 4426s-4431s	44
1915	Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. <b>2006</b> , 24, 4721-30	287
1914	Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. <b>2006</b> , 5, 1154-65	79
1913	Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. <b>2006</b> , 12, 7406-13	17
1912	CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. <b>2006</b> , 98, 1714-23	93
1911	Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. <b>2006</b> , 12, 7117-25	104
1910	Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. <b>2006</b> , 24, 5253-8	163
1909	Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. <b>2006</b> , 12, 4421s-4425s	57
1908	Exercise induced bronchoconstriction in elite athletes: measuring the fall. <b>2006</b> , 61, 94-6	14
1907	Expanding role of chemotherapy in lung cancer. <b>2006</b> , 17 Suppl 10, x101-7	2
1906	Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. <b>2006</b> , 24, 5025-33	133
1905	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. <b>2006</b> , 12, 839-44	597
1904	Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. <b>2006</b> , 12, 4441s-4445s	74
1903	Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. <b>2007</b> , 29, 128-33	11
1902	Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. <b>2006</b> , 24, 2252-60	122

1901	Second-line chemotherapy for non-small cell lung cancer. <b>2006</b> , 17 Suppl 5, v68-71	8
1900	Respecting cancer drug transportability: a basis for successful lead selection. <b>2006</b> , 98, 1098-9	2
1899	Erlotinib: optimizing therapy with predictors of response?. <b>2006</b> , 12, 2961-3	20
1898	Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. <b>2006</b> , 12, 4416s-4420s	113
1897	Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer. <b>2006</b> , 36, 12-6	4
1896	Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. <b>2006</b> , 11, 358-73	54
1895	Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when, and how?. <b>2006</b> , 12, 4409s-4415s	44
1894	Targeted therapies in combination with chemotherapy in non-small cell lung cancer. <b>2006</b> , 12, 4451s-4457s	16
1893	Epidermal growth factor receptor mutation testing in the care of lung cancer patients. <b>2006</b> , 12, 4403s-4408s	68
1892	Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. <b>2006</b> , 12, 2281-8	65
1891	Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. <b>2006</b> , 2, 47-51	6
1890	Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. <b>2006</b> , 66, 8163-71	315
1889	Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. <b>2006</b> , 17 Suppl 2, ii46-48	20
1888	Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. <b>2006</b> , 12, 3652-6	54
1887	OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. <b>2006</b> , 66, 1015-24	59
1886	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. <b>2006</b> , 12, 3908-14	479
1885	Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. <b>2006</b> , 24, 3831-7	255
1884	Possible problem with Optipen Pro-1: should diabetic patients continue to use this product?. <b>2006</b> , 29, 1710-1	1

1883	Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. <b>2006</b> , 8, 67-78	177
1882	Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. <b>2006</b> , 24, 2800-7	96
1881	Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. <b>2006</b> , 24, 656-62	120
1880	Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line. <b>2006</b> , 24, 2700-1	3
1879	Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. <b>2006</b> , 66, 10100-11	291
1878	Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. <b>2006</b> , 12, 5659-67	180
1877	Lung cancer genetics and pharmacogenomics. <b>2006</b> , 115, 298-302	2
1876	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. <b>2006</b> , 17 Suppl 2, ii42-45	23
1875	Novel targeted approaches in non-small cell lung cancer (NSCLC). <b>2006</b> , 17 Suppl 5, v91-3	3
1874	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. <b>2006</b> , 17, 1120-7	75
1873	Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art. <b>2006</b> , 2, 67-72	
1872	The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. <b>2006</b> , 12, 4372s-4376s	68
1871	Non-small cell lung cancer: second-line and beyond. <b>2006</b> , 17 Suppl 10, x97-100	6
1870	Multi-target inhibitors in non-small cell lung cancer (NSCLC). <b>2006</b> , 17 Suppl 2, ii55-57	5
1869	Treatment of advanced non-small cell lung cancer. <b>2006</b> , 17 Suppl 2, ii36-41	23
1868	Chemotherapy of advanced NSCLC in special patient population. <b>2006</b> , 17 Suppl 5, v72-8	13
1867	Gefitinib: an adverse effects profile. <b>2006</b> , 5, 469-79	32
1866	Epidermal growth factor receptor inhibition and non-small cell lung cancer. <b>2006</b> , 43, 291-323	14

1865	Recent developments in the chemotherapeutic options for nonsmall cell lung cancer. <b>2006</b> , 6, 1397-410	
1864	The cancer and leukemia group B respiratory committee. <b>2006</b> , 12, 3581s-8s	2
1863	Effects of smoking on the pharmacokinetics of erlotinib. <b>2006</b> , 12, 2166-71	240
1862	Phase II study of erlotinib in patients with advanced biliary cancer. <b>2006</b> , 24, 3069-74	261
1861	A new era for bronchioloalveolar carcinoma: current state of the art and recent advances in biologically targeted therapy. <b>2006</b> , 6, 1411-9	1
1860	Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474. <b>2006</b> , 6, 545-51	10
1859	Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. <b>2006</b> , 17, 1185-96	60
1858	Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. <b>2006</b> , 24, 4405-11	121
1857	Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. <b>2006</b> , 11, 602-11	27
1856	Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. <b>2006</b> , 24, 1219-20; author reply 1220-1	88
1855	Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. <b>2007</b> , 12, 191-200	92
1854	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <b>2007</b> , 12, 325-30	54
1853	Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. <b>2007</b> , 25, 5777-84	177
1852	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. <b>2007</b> , 7, 821-36	9
1851	Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. <b>2007</b> , 13, 2795-803	222
1850	Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. <b>2007</b> , 25, 3936-44	105
1849	A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer. <b>2007</b> , 13, 1816-22	42
1848	Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. <b>2007</b> , 25, 5155-7	35

1847	Targeting HER2 in prostate cancer: where to next?. <b>2007</b> , 25, 241-3	39
1846	Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. <b>2007</b> , 72, 248-58	62
1845	Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. <b>2007</b> , 6, 471-83	76
1844	Uncommon tumors and exceptional therapies: paradox or paradigm?. <b>2007</b> , 6, 1175-9	42
1843	Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. <b>2007</b> , 25, 3055-60	55
1842	The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. <b>2007</b> , 6, 1180-5	32
1841	Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. <b>2007</b> , 13, 6175-81	78
1840	New targets for non-small-cell lung cancer therapy. <b>2007</b> , 7, 1423-37	33
1839	X-linked inhibitor of apoptosis protein as a therapeutic target. <b>2007</b> , 11, 1459-71	42
1838	CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. <b>2007</b> , 4, 603-7	16
1837	HER family inhibitors in pancreatic cancer: current status and future directions. <b>2007</b> , 11, 337-47	5
1836	Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. <b>2007</b> , 13, s4597-601	33
1835	'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. <b>2007</b> , 97, 1560-6	66
1834	Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. <b>2007</b> , 7, 415-22	41
1833	Tyrosine kinase mutations in human cancer. <b>2007</b> , 7, 77-84	53
1832	Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor. <b>2007</b> , 3, 69-77	6
1831	Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. <b>2007</b> , 25, 1747-52	93
1830	Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. <b>2007</b> , 18 Suppl 9, ix150-5	12

1829	Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer. <b>2007</b> , 18 Suppl 10, x32-41	15
1828	Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. <b>2007</b> , 67, 5779-88	102
1827	Optimizing Anti-EGFR Strategies in Cancer Treatment. <b>2007</b> , 3, 267-275	
1826	Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. <b>2007</b> , 13, 523-31	19
1825	The development of targeted therapies for hepatocellular cancer. <b>2007</b> , 13, 3292-300	7
1824	Targeted therapies for non-small cell lung cancer. <b>2007</b> , 13, 2810-31	13
1823	Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. <b>2007</b> , 12, 211-20	43
1822	Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. <b>2007</b> , 46, 1113-7	30
1821	Respiratory Failure in Cancer Patients: Non-Infectious Complications of Antineoplastic Agents for Solid Tumors. <b>2007</b> , 3, 229-232	
1820	Erlotinib in non-small cell lung cancer treatment: current status and future development. <b>2007</b> , 12, 840-9	90
1819	Lung cancer vaccines. <b>2007</b> , 7, 469-84	4
1818	Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. <b>2007</b> , 99, 838-46	258
1817	Update in lung cancer 2006. <b>2007</b> , 175, 868-74	7
1816	Review of targeted cancer therapies for the palliative care provider: Part 1: small molecules. <b>2007</b> , 15, 171-176	
1815	A translational view of the molecular pathogenesis of lung cancer. <b>2007</b> , 2, 327-43	237
1814	Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. <b>2007</b> , 2, 537-43	32
1813	1E10 anti-idiotypic vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. <b>2007</b> , 6, 1847-52	58
1812	EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). <b>2007</b> , 2, 423-9	68

1811	Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. <b>2007</b> , 8, 1211-20	2
1810	Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. <b>2007</b> , 15, 279-86	74
1809	Risk-based and diagnostics-linked personalized medicine for cancer. <b>2007</b> , 4, 33-43	3
1808	Drug insight: advances in renal cell carcinoma and the role of targeted therapies. <b>2007</b> , 4, 470-9	26
1807	A review of vaccine clinical trials for non-small cell lung cancer. <b>2007</b> , 7, 89-102	10
1806	Emerging drugs for targeted therapy of bladder cancer. <b>2007</b> , 12, 435-48	5
1805	Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. <b>2007</b> , 11, 1287-98	23
1804	Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. <b>2007</b> , 7, 666-73	18
1803	[An approach to individualised therapy of non-small cell lung carcinoma (NSCLC)--relevance of molecular predictive and prognostic factors]. <b>2007</b> , 61, 731-8	5
1802	Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. <b>2007</b> , 6, 661-7	72
1801	Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. <b>2007</b> , 1, 203-7	2
1800	Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors. <b>2007</b> , 3, 277-83	28
1799	Clinical trials in the elderly--a concept comes of age. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 1575-659.2	57
1798	Recent advances in targeted therapy for non-small cell lung cancer. <b>2007</b> , 11, 245-57	24
1797	Does erlotinib improve symptoms in patients with lung cancer?. <b>2007</b> , 4, 146-7	2
1796	Erlotinib in cancer treatment. <b>2007</b> , 18 Suppl 6, vi35-41	72
1795	Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. <b>2007</b> , 25, 146-62	79
1794	Bevacizumab and non-small-cell lung cancer: starving the enemy to survive. <b>2007</b> , 7, 1107-19	4

1793	Inhibition of Jun NH2-terminal kinases suppresses the growth of experimental head and neck squamous cell carcinoma. <b>2007</b> , 13, 5910-7	36
1792	Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. <b>2007</b> , 13, 7086-92	58
1791	Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer. <b>2007</b> , 25, 751-3	6
1790	Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. <b>2007</b> , 67, 7807-14	153
1789	The potential of antiangiogenic therapy in non-small cell lung cancer. <b>2007</b> , 13, 1961-70	57
1788	Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. <b>2007</b> , 18, 447-52	35
1787	Phosphorylation and activation of cell division cycle associated 8 by aurora kinase B plays a significant role in human lung carcinogenesis. <b>2007</b> , 67, 4113-22	90
1786	Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. <b>2007</b> , 6, 532-41	160
1785	Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. <b>2007</b> , 13, 3413-22	171
1784	Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. <b>2007</b> , 67, 2046-53	133
1783	Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. <b>2007</b> , 13, 434-42	75
1782	Biology of interactions: antiepidermal growth factor receptor agents. <b>2007</b> , 25, 4057-65	184
1781	Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. <b>2007</b> , 3, 247-54	19
1780	Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. <b>2007</b> , 99, 1455-61	143
1779	Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations. <b>2007</b> , 13, s4632-6	22
1778	A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. <b>2007</b> , 67, 6253-62	107
1777	Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. <b>2007</b> , 25, 2719-26	91
1776	On how increasing numbers of newer cancer therapies further delay referral to hospice: the increasing palliative care imperative. <b>2007</b> , 24, 126-30	27



1775	Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease. <b>2007</b> , 12, 331-7	25
1774	PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. <b>2007</b> , 67, 11924-32	589
1773	FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. <b>2007</b> , 12, 713-8	302
1772	Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. <b>2007</b> , 13, 4849-57	74
1771	Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. <b>2007</b> , 25, 2528-33	129
1770	Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. <b>2007</b> , 25, 4350-7	92
1769	3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. <b>2007</b> , 67, 11463-9	63
1768	Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. <b>2007</b> , 13, 1511-5	78
1767	Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. <b>2007</b> , 25, 2377-82	102
1766	Targeted therapies in lung cancer. <b>2007</b> , 18 Suppl 9, ix135-42	32
1765	Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?. <b>2007</b> , 25, 2504-5	5
1764	Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. <b>2007</b> , 67, 10417-27	51
1763	Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. <b>2007</b> , 13, s4606-12	42
1762	Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. <b>2007</b> , 18, 761-7	26
1761	Clairvoyance or reliable prediction of the future?. <b>2007</b> , 18, 407-8	2
1760	ESMO Handbook on Principles of Translational Research. <b>2007</b> ,	
1759	Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. <b>2007</b> , 6, 2515-24	106
1758	Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. <b>2007</b> , 13, s4628-31	38

1757	The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. <b>2007</b> , 12, 1183-93	51
1756	Current status and future of target-based therapeutics. <b>2007</b> , 7, 273-84	6
1755	Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. <b>2007</b> , 3, 226-235	
1754	Methodological Issues of Clinical Research with EGFR Inhibitors. <b>2007</b> , 3, 292-302	3
1753	Lung cancer incidence in never smokers. <b>2007</b> , 25, 472-8	388
1752	Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?. <b>2007</b> , 99, 1422-3	9
1751	Non-small cell lung cancer: new hope for a chronic illness. <b>2007</b> , 34, 963-70	7
1750	Lessons learned in the management of advanced pancreatic cancer. <b>2007</b> , 25, 1949-52	29
1749	Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. <b>2007</b> , 25, 1377-82	98
1748	Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. <b>2007</b> , 13, 3913-21	324
1747	Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. <b>2007</b> , 13, s4617-22	39
1746	Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer. <b>2007</b> , 13, s4589-92	11
1745	The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. <b>2007</b> , 18, 453-60	62
1744	Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. <b>2007</b> , 18 Suppl 2, ii30-1	5
1743	Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. <b>2007</b> , 2, S125-7	5
1742	Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). <b>2007</b> , 2, 299-305	51
1741	Multidisciplinary Team Management of Lung Cancer. <b>2007</b> ,	
1740	The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. <b>2007</b> , 2, 414-22	35

1739	Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC). <b>2007</b> , 2, 827-30	48
1738	Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. <b>2007</b> , 2, 402-7	56
1737	Schedule-dependent interaction between the proteasome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines. <b>2007</b> , 2, 715-21	19
1736	Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. <b>2007</b> , 2, 141-6	28
1735	Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. <b>2007</b> , 2, 758-61	31
1734	EGFR targeting of solid tumors. <b>2007</b> , 14, 295-304	220
1733	M02-03: Tumor hypoxia and metastasis in non-small cell lung cancers. <b>2007</b> , 2, S154-S155	2
1732	Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. <b>2007</b> , 110, 1079-80	39
1731	Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. <b>2007</b> , 2, 430-9	159
1730	Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. <b>2007</b> , 2, 845-53	96
1729	Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. <b>2007</b> , 2 Suppl 2, S68-76	33
1728	Introduction: Diagnosis and management of lung cancer: ACCP evidence-based clinical practice guidelines (2nd Edition). <b>2007</b> , 132, 20S-22S	22
1727	E10-04: Management in advanced lung cancer:pain control. <b>2007</b> , 2, S247-S249	
1726	E13-01: Insights into thymic epithelial tumor: pathology. <b>2007</b> , 2, S258-S260	
1725	Pharmacology of Epidermal Growth Factor Inhibitors. <b>2007</b> , 22, 24-39	9
1724	E08-03: Innovative bronchoscopic diagnostic techniques: electromagnetic navigation. <b>2007</b> , 2, S239-S241	
1723	M03-04: Selecting lung cancer patients to targeted therapies based on protein expression by immunohistochemistry. <b>2007</b> , 2, S157-S158	1
1722	A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. <b>2007</b> , 2, 306-11	38

1721	The Future of Anti-EGFR Therapy. <b>2007</b> , 22, 88-93	2
1720	Combination of standard chemotherapy and targeted agents. <b>2007</b> , 2, S19-23	2
1719	M02-02: Update of EGFR inhibitors and radiation in the management of non-small cell lung cancer—where do we go next?. <b>2007</b> , 2, S153-S154	2
1718	Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges. <b>2007</b> , 22, 10-23	3
1717	Non-small cell lung cancer in octogenarians: treatment practices and preferences. <b>2007</b> , 2, 1029-35	30
1716	Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer. <b>2007</b> , 17, 313-9	49
1715	Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. <b>2007</b> , 25, 3448-55	123
1714	Outcome of Lung Cancer Patients Admitted to the Intensive Care Unit. <b>2007</b> , 14, 281-285	2
1713	Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. <b>2007</b> , 18, 835-7	26
1712	Small cell lung cancer and targeted therapies. <b>2007</b> , 19, 103-8	24
1711	Targeted therapies and non-small-cell lung cancer: new developments. <b>2007</b> , 19, 75-7	3
1710	Diagnosis and treatment of bronchioloalveolar carcinoma. <b>2007</b> , 13, 290-6	16
1709	Lung cancer adjuvant therapy. <b>2007</b> , 13, 210-6	2
1708	Promising new therapies for malignant gliomas. <b>2007</b> , 13, 349-54	18
1707	Signal Transduction Therapy: Challenges to Clinical Trial Design. <b>2007</b> , 2, 21-30	1
1706	Prognosis of lung cancer patients with life-threatening complications. <b>2007</b> , 131, 840-846	98
1705	Bronchioloalveolar lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). <b>2007</b> , 132, 306S-13S	42
1704	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). <b>2007</b> , 2007, 207-210	

1703	[Small cell lung cancer--state of the art and future perspectives]. <b>2007</b> , 13, 587-604	5
1702	Combined targeted therapies in non-small cell lung cancer: a winner strategy?. <b>2007</b> , 19, 98-102	20
1701	Small peripheral pulmonary adenocarcinoma: morphologic and molecular update. <b>2007</b> , 14, 120-8	6
1700	Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. <b>2007</b> , 69, 596-602	30
1699	Targeted therapies in bladder cancer--an update. <b>2007</b> , 25, 433-8	70
1698	Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. <b>2007</b> , 83, 1257-64	68
1697	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. <b>2007</b> , 10, 81-100	62
1696	EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. <b>2007</b> , 43, 520-6	66
1695	The proteasome: a worthwhile target for the treatment of solid tumours?. <b>2007</b> , 43, 1125-33	80
1694	Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. <b>2007</b> , 33, 203-12	42
1693	Targeting novel and established therapies for non-small cell lung cancer. <b>2007</b> , 250, 9-16	10
1692	[Targeted therapies and radiotherapy in lung cancer]. <b>2007</b> , 11, 77-83	3
1691	EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. <b>2007</b> , 83, 238-48	157
1690	SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. <b>2007</b> , 170, 366-76	125
1689	The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. <b>2007</b> , 57, 96-102	15
1688	Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. <b>2007</b> , 25, 2248-55	198
1687	Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. <b>2007</b> , 12, 90-8	138
1686	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. <b>2007</b> , 18, 752-60	232

1685	Phase II clinical trial of chemotherapy-naïve patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. <b>2007</b> , 25, 760-6	279
1684	EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. <b>2007</b> , 18, 99-103	116
1683	Carcinoma do pulmão de pequenas células – Estado da arte e perspectivas futuras. <b>2007</b> , 13, 587-604	5
1682	Improving patient management in metastatic non-small cell lung cancer. <b>2007</b> , 57 Suppl 2, S12-7	14
1681	The place of targeted therapy in the patient management of non-small cell lung cancer. <b>2007</b> , 57 Suppl 2, S18-23	17
1680	How could pharmacogenomics help improve patient survival?. <b>2007</b> , 57 Suppl 2, S35-41	9
1679	Growth factor signalling: ample opportunities for pharmaceutical interventions in oncology. <b>2007</b> , 5, 427-429	
1678	Fulminant hepatic failure secondary to erlotinib. <b>2007</b> , 5, 917-20	35
1677	Apoptosis, Senescence, and Cancer. <b>2007</b> ,	6
1676	KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. <b>2007</b> , 13, 2890-6	527
1675	Pharmacogenomics of Anticancer Agents: Implications for Clinical Pharmacy Practice. <b>2007</b> , 20, 246-251	1
1674	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. <b>2007</b> , 1, 183-91	2
1673	Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature. <b>2007</b> , 12, 201-10	69
1672	Perspectives in adjuvant chemotherapy in NSCLC. <b>2007</b> , 1, 99-110	1
1671	Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. <b>2007</b> , 23, 1509-15	27
1670	HER-2-positive breast cancer: hope beyond trastuzumab. <b>2007</b> , 21, 69-77	24
1669	A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective. <b>2007</b> , 10, 255-271	10
1668	Emerging drugs for non-small-cell lung cancer. <b>2007</b> , 12, 449-60	20

1667	Lung cancer in never smokers: a review. <b>2007</b> , 25, 561-70	494
1666	Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. <b>2007</b> , 16, 239-49	112
1665	LUNG CANCERS. <b>2007</b> , 25, 48-52	1
1664	Elderly lung cancer patients: what treatment strategies?. <b>2007</b> , 7, 1331-4	4
1663	Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. <b>2007</b> , 6, 2652-63	32
1662	Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. <b>2007</b> , 25, 3266-73	44
1661	Small molecule signal transduction inhibitors for the treatment of solid tumors. <b>2007</b> , 25, 347-65	12
1660	Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. <b>2007</b> , 25, 587-95	515
1659	Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. <b>2007</b> , 25, 1545-52	777
1658	Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. <b>2007</b> , 25, 4270-7	254
1657	Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. <b>2007</b> , 25, 4278-84	176
1656	Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. <b>2007</b> , 25, 1960-6	2883
1655	Lung cancer in the elderly. <b>2007</b> , 25, 1898-907	116
1654	Population cible et facteurs prđictifs de survie et d'efficacit'des anti-HER1/EGFR. <b>2007</b> , 63, 10-11	
1653	Utilisation des inhibiteurs des TK dans des situations particuliřes. <b>2007</b> , 63, 14-15	
1652	[Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer]. <b>2007</b> , 27, 353-63	6
1651	Rřultats cliniques observřs avec les inhibiteurs de tyrosine kinase. <b>2007</b> , 63, 7-9	
1650	[New biological treatments for lung cancer]. <b>2007</b> , 63, 20-8	1

1649	[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?]. <b>2007</b> , 63, 147-54	0
1648	Cancer bronchique non ^petites cellules : du traitement de la rechute aux traitements des rechutes. <b>2007</b> , 24, 108-113	0
1647	Évolution du traitement systématique des cancers bronchiques non ^petites cellules en 2007 : les thèmes « clés » des congrès de l'ASCO et du WCLC 2007. <b>2007</b> , 63, 37-41	
1646	Quel traitement pour un patient de PS-2/3 ayant un cancer bronchique non ^petites cellules (CBNPC). <b>2007</b> , 24, 120-124	5
1645	Perspectives et développements futurs des inhibiteurs de l'EGFR. <b>2007</b> , 63, 18-20	
1644	Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. <b>2007</b> , 67, 11012-20	252
1643	[Management of non-small cell lung carcinoma following docetaxel-cisplatin. Results of an epidemiologic survey]. <b>2007</b> , 24, 1099-106	0
1642	Les inhibiteurs de tyrosine kinase de l'EGFR dans le traitement du CBNPC. <b>2007</b> , 24, 188-197	1
1641	Les études biologiques actuelles doivent-elles influencer nos choix thérapeutiques ?. <b>2007</b> , 63, 42-48	
1640	Women and lung cancer: epidemiology, tumor biology, and emerging trends in clinical research. <b>2007</b> , 55, 15-23	70
1639	Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC). <b>2007</b> , 55, 125-7	4
1638	Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. <b>2007</b> , 55, 115-21	25
1637	A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. <b>2007</b> , 55, 181-5	51
1636	Recurrent responses to non-small cell lung cancer brain metastases with erlotinib. <b>2007</b> , 56, 135-7	40
1635	A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status. <b>2007</b> , 56, 255-62	9
1634	Significant drug interaction: phenytoin toxicity due to erlotinib. <b>2007</b> , 57, 404-6	30
1633	Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. <b>2007</b> , 57, 193-200	18
1632	Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy. <b>2007</b> , 58, 73-9	3



1631	Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. <b>2007</b> , 58, 95-103	140
1630	Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer. <b>2007</b> , 58, 414-7	31
1629	Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer. <b>2007</b> , 58, 253-9	11
1628	Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer. <b>2007</b> , 58, 425-8	35
1627	The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. <b>2007</b> , 5, 203-20	323
1626	Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature. <b>2007</b> , 8, 319-26	3
1625	[Biologic therapy: current and future applications in oncology]. <b>2007</b> , 129, 184-93	3
1624	Epidermal growth factor receptor inhibitors in non-small cell lung cancer. <b>2007</b> , 67, 1125-38	12
1623	Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management. <b>2007</b> , 67, 1403-10	29
1622	EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. <b>2007</b> , 67, 2045-75	97
1621	Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib. <b>2007</b> , 27, 499-503	4
1620	Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. <b>2007</b> , 6, 529-31	27
1619	A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients. <b>2007</b> , 7 Suppl 1, S8-15	2
1618	Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer. <b>2007</b> , 8, 420-4	2
1617	Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer. <b>2007</b> , 8, 425-8	4
1616	Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. <b>2007</b> , 8 Suppl 2, S79-85	55
1615	Role of target expression as inclusion criteria. <b>2007</b> , 5, 41-42	
1614	Adaptive trial design and its role in oncology: An EMEA perspective. <b>2007</b> , 5, 43-44	2

1613	Current stumbling blocks in oncology drug development. <b>2007</b> , 135-49	2
1612	Erlotinib in non-small-cell lung cancer. <b>2007</b> , 8, 2579-92	10
1611	Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule. <b>2007</b> , 9, 113-124	7
1610	Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure. <b>2007</b> , 2, 96-8	8
1609	MTP23-01: Salvage therapy for NSCLC. <b>2007</b> , 2, S289-S290	
1608	Erlotinib-associated acute pneumonitis: report of two cases. <b>2007</b> , 14, 167-70	16
1607	Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer. <b>2007</b> , 22, 393-9	9
1606	EGFR inhibitors in the treatment of lung cancer. <b>2007</b> , 30, 476	1
1605	MUC-1 (CA 15â Antigen) as a Highly Reliable Predictor of Response to EGFR Inhibitors in Patients with Bronchioloalveolar Carcinoma: An Experience on 26 Patients. <b>2007</b> , 22, 307-311	
1604	Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer. <b>2007</b> , 2, S12-4	6
1603	Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case series. <b>2007</b> , 30, 515-8	3
1602	Combination of target agents: challenges and opportunities. <b>2007</b> , 2, S4-6	3
1601	EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB. <b>2007</b> , 155-178	
1600	The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. <b>2007</b> , 120, 1239-47	110
1599	Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer. <b>2007</b> , 121, 1162-7	27
1598	Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. <b>2007</b> , 121, 2387-94	96
1597	Targeting cell signaling pathways for drug discovery: an old lock needs a new key. <b>2007</b> , 102, 580-92	107
1596	Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. <b>2007</b> , 109, 658-67	169

1595	Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. <b>2007</b> , 110, 581-9	221
1594	Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients. <b>2007</b> , 110, 2293-303	61
1593	Response to dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. <b>2007</b> , 110, 2775-84	24
1592	Targeting mTOR signaling in lung cancer. <b>2007</b> , 63, 172-82	61
1591	The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. <b>2007</b> , 26, 5023-7	94
1590	From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. <b>2007</b> , 25, 1134-43	165
1589	Epidermal growth factor receptor mutations in lung cancer. <b>2007</b> , 7, 169-81	2272
1588	Lung cancer in never smokers--a different disease. <b>2007</b> , 7, 778-90	1034
1587	10-year follow-up of gene-modified adenoviral-based therapy in 146 non-small-cell lung cancer patients. <b>2007</b> , 14, 762-3	10
1586	Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. <b>2007</b> , 96, 808-14	102
1585	Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. <b>2007</b> , 96, 857-63	80
1584	Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?. <b>2007</b> , 97, 857-61	39
1583	Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha. <b>2007</b> , 99, 1539-45	14
1582	A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. <b>2008</b> , 101, 20-5	34
1581	Novel targeted therapies for advanced esophageal cancer. <b>2007</b> , 20, 365-71	9
1580	Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. <b>2008</b> , 33, 46-9	14
1579	Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. <b>2007</b> , 98, 226-30	32
1578	Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. <b>2007</b> , 98, 1977-84	29

1577	Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. <b>2007</b> , 10 Suppl 2, S138-45	29
1576	Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. <b>2007</b> , 23, 42-5	40
1575	Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin. <b>2007</b> , 3, 66-78	14
1574	Management of metastatic carcinoma of the uveal tract: an evidence-based analysis. <b>2007</b> , 35, 553-65	61
1573	Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. <b>2007</b> , 8, 548-53	69
1572	A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. <b>2007</b> , 8, 568-71	18
1571	Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. <b>2007</b> , 8 Suppl 2, S61-7	19
1570	A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. <b>2007</b> , 7, 142	60
1569	Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. <b>2007</b> , 12, 81-93	193
1568	A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. <b>2007</b> , 104, 727-31	109
1567	Targeted agents and esophageal cancer--the next step?. <b>2007</b> , 17, 62-9	21
1566	Future strategies for targeted therapies and tailored patient management in pancreatic cancer. <b>2007</b> , 34, 354-64	8
1565	Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. <b>2007</b> , 14, 942-53	112
1564	Molecular staging of prostate cancer in the year 2007. <b>2007</b> , 25, 19-30	35
1563	[Non-small cell lung cancer - diagnostics and stage-adapted therapy]. <b>2007</b> , 102, 981-8; quiz 989-90	2
1562	Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. <b>2007</b> , 56, 1637-44	78
1561	A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. <b>2007</b> , 59, 467-75	46
1560	Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. <b>2007</b> , 59, 621-9	8

1559	Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models. <b>2007</b> , 59, 651-9	18
1558	Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy. <b>2007</b> , 60, 189-95	5
1557	Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer. <b>2007</b> , 60, 267-74	2
1556	The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers. <b>2008</b> , 61, 23-32	16
1555	Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. <b>2007</b> , 25, 351-5	7
1554	The role of the mitochondria in mediating cytotoxicity of anti-cancer therapies. <b>2007</b> , 39, 13-21	17
1553	Pharmacologie des thfapeutiques ciblès. <b>2007</b> , 9, 773-777	
1552	[NSCLC: update on second line therapy following ASCO 2007]. <b>2007</b> , 157, 540-4	
1551	["Targeted Therapies" in NSCLC - present and future]. <b>2007</b> , 157, 545-53	
1550	[TRUST study: general practice relevant data on erlotinib in NSCLC]. <b>2007</b> , 157, 579-80	
1549	Signalbermittlungsinhibitoren. <b>2007</b> , 13, 213-226	4
1548	Symptomkontrollierende Effekte der Chemotherapie. <b>2007</b> , 13, 619-624	1
1547	[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms]. <b>2007</b> , 119, 259-66	10
1546	Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. <b>2007</b> , 8, 15-27	98
1545	"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?". <b>2007</b> , 8, 28-37	16
1544	Current status of signal transduction modulators in the treatment of gynecologic malignancies. <b>2007</b> , 8, 383-92	5
1543	Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?. <b>2007</b> , 9, 255-64	17
1542	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. <b>2007</b> , 2, 3-12	9

1541	Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study. <b>2007</b> , 2, 63-71	1
1540	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. <b>2008</b> , 27, 387-402	26
1539	Clinical biomarkers of angiogenesis inhibition. <b>2008</b> , 27, 415-34	39
1538	Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. <b>2008</b> , 25, 685-93	169
1537	Measuring health-related quality of life in drug clinical trials: is it given due importance?. <b>2008</b> , 30, 154-60	17
1536	The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. <b>2008</b> , 64, 31-41	96
1535	Evaluation of [(18F)]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. <b>2008</b> , 35, 1089-99	87
1534	What oncologists need and require from nuclear medicine. <b>2008</b> , 35, 1761-5	5
1533	Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. <b>2008</b> , 61, 489-96	69
1532	Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. <b>2008</b> , 62, 605-20	29
1531	Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer. <b>2008</b> , 62, 173-80	26
1530	[Lung cancer]. <b>2008</b> , 103, 311-20	1
1529	[Molecular tumour therapy: antibodies and small molecules]. <b>2008</b> , 49, 581-92	1
1528	Can we predict the response to epidermal growth factor receptor targeted therapy?. <b>2008</b> , 3, 87-99	1
1527	Advanced non-small cell lung cancer therapy: historical and future perspectives. <b>2008</b> , 3, 135-147	2
1526	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. <b>2008</b> , 3, 173-186	3
1525	Antiangiogenic treatments of advanced non-small cell lung cancer. <b>2008</b> , 3, 187-196	2
1524	Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies. <b>2008</b> , 3, 235-243	3

1523	Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. <b>2008</b> , 56, 97-103	32
1522	From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. <b>2008</b> , 56, 43-53	52
1521	Abstracts. <b>2008</b> , 9, 1-122	0
1520	The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC). <b>2008</b> , 9, 313-25	2
1519	Cisplatin versus carboplatin in NSCLC: is there one "best" answer?. <b>2008</b> , 9, 326-42	19
1518	Cancer pain: perspectives of a medical oncologist. <b>2008</b> , 12, 270-6	3
1517	Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations. <b>2008</b> , 1, 13-16	0
1516	Adjuvant therapy in non-small cell lung cancer: Current status and future perspectives. <b>2008</b> , 1, 57-60	0
1515	Das fortgeschrittene nichtkleinzellige Lungenkarzinom. <b>2008</b> , 3, 26-36	
1514	Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens. <b>2008</b> , 25, 133-6	4
1513	The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma. <b>2008</b> , 25, 408-14	4
1512	Cardiac toxicity: old and new issues in anti-cancer drugs. <b>2008</b> , 10, 35-46	56
1511	Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC). <b>2008</b> , 10, 198-203	2
1510	Prognoseadaptierte Therapie beim fortgeschrittenen CUP-Syndrom. <b>2008</b> , 14, 920-930	0
1509	Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patients. <b>2008</b> , 13, 442-6	11
1508	Docetaxel as salvage chemotherapy in patients with advanced non-small cell lung cancer after failure of cytotoxic agents and gefitinib treatment. <b>2008</b> , 7, 495-499	1
1507	Therapie des Lungenkarzinoms. <b>2008</b> , 5, 259-266	
1506	Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. <b>2008</b> , 16, 557-66	94

1505	The management of cancer in the elderly: targeted therapies in oncology. <b>2008</b> , 5, 16	9
1504	Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. <b>2008</b> , 112, 1114-21	63
1503	Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. <b>2008</b> , 112, 2749-55	21
1502	Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first : result of a randomized pilot study. <b>2008</b> , 113, 143-9	86
1501	Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. <b>2008</b> , 113, 808-14	98
1500	Aggressiveness of care in a prospective cohort of patients with advanced NSCLC. <b>2008</b> , 113, 826-33	87
1499	Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). <b>2008</b> , 113, 847-53	143
1498	Systemic cancer therapy: evolution over the last 60 years. <b>2008</b> , 113, 1857-87	42
1497	EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. <b>2008</b> , 69, 359-372	34
1496	Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. <b>2008</b> , 122, 2612-20	39
1495	Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva. <b>2008</b> , 215, 827-36	29
1494	Expression and mutational analysis of MET in human solid cancers. <b>2008</b> , 47, 1025-37	246
1493	Molecular targeted therapies in hepatocellular carcinoma. <b>2008</b> , 48, 1312-27	801
1492	Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. <b>2008</b> , 66, 155-62	38
1491	Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. <b>2008</b> , 67, 16-26	14
1490	The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. <b>2008</b> , 68, 29-36	39
1489	Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. <b>2008</b> , 68, 183-96	26
1488	Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: current status and future development. <b>2008</b> , 68, 222-32	16



1487	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. <b>2008</b> , 19, 717-23	225
1486	Randomized phase III clinical trial designs for targeted agents. <b>2008</b> , 14, 4358-67	79
1485	Targeted therapy in the treatment of solid tumors: practice contradicts theory. <b>2008</b> , 73, 605-18	30
1484	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). <b>2008</b> , 98, 907-14	175
1483	Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. <b>2008</b> , 98, 1608-13	133
1482	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. <b>2008</b> , 99, 911-22	145
1481	Survival from lung cancer in England and Wales up to 2001. <b>2008</b> , 99 Suppl 1, S43-6	6
1480	Emerging ethnic differences in lung cancer therapy. <b>2008</b> , 99, 1757-62	101
1479	Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. <b>2008</b> , 14, 822-7	835
1478	Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. <b>2008</b> , 83, 477-84	44
1477	Painful pustular eruption in the groin and the scrotum induced by erlotinib. <b>2008</b> , 22, 507-8	1
1476	Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. <b>2008</b> , 99, 1747-53	19
1475	Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer. <b>2008</b> , 99, 2455-60	29
1474	Persistent CD4+ T cell depression following combination alefacept and methotrexate therapy. <b>2008</b> , 47, 1204-6	
1473	How important is the pus culture obtained from epithelial growth factor receptor (EGFR) inhibitors' associated rash?. <b>2008</b> , 47, 1203-4	3
1472	[Lung cancer in Spain: the current situation. 2008 SESPAS Report]. <b>2008</b> , 22 Suppl 1, 169-78	2
1471	Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. <b>2008</b> , 8, 3	46
1470	Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. <b>2008</b> , 9, 59-60	27

1469	Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective. <b>2008</b> , 9, 78-84	16
1468	A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer. <b>2008</b> , 9, 154-9	8
1467	Improving health-related quality of life in non-small-cell lung cancer with current treatment options. <b>2008</b> , 9, 206-12	23
1466	Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. <b>2008</b> , 9, 232-4	32
1465	An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. <b>2008</b> , 9, 235-8	27
1464	Will FLEX allow us flexibility in the therapy of advanced non-small-cell lung cancer? Insights from the 2008 American Society of Clinical Oncology Meeting. <b>2008</b> , 9, 249-51	5
1463	Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer. <b>2008</b> , 9 Suppl 3, S109-15	14
1462	New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer. <b>2008</b> , 9 Suppl 3, S122-8	10
1461	Non-small cell lung cancer in the elderly: defining treatment options. <b>2008</b> , 35, 590-6	23
1460	Targeted agents in cancer therapy. <b>2008</b> , 36, 33-37	4
1459	Lung cancer and its management. <b>2008</b> , 36, 162-167	
1458	Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. <b>2008</b> , 5, 44-54	68
1457	Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. <b>2008</b> , 93, 2057-62	122
1456	Targeted therapies for patients with germ cell tumors. <b>2008</b> , 17, 511-22	17
1455	Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy. <b>2008</b> , 59, 64-8	3
1454	Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer. <b>2008</b> , 60, 231-9	2
1453	Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. <b>2008</b> , 60, 240-5	21
1452	Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer. <b>2008</b> , 61, 61-6	8

1451	Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?. <b>2008</b> , 61, 73-81	21
1450	A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly. <b>2008</b> , 61, 214-9	14
1449	Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). <b>2008</b> , 61, 405-15	56
1448	Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: a prospective study. <b>2008</b> , 61, 378-84	8
1447	Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. <b>2008</b> , 61, 262-5	14
1446	EGFR FISH versus mutation: different tests, different end-points. <b>2008</b> , 60, 160-5	39
1445	High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. <b>2008</b> , 62, 78-84	24
1444	Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: a case report. <b>2008</b> , 61, 270-3	7
1443	Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial. <b>2008</b> , 62, 334-43	14
1442	Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. <b>2008</b> , 62, 193-201	36
1441	Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib. <b>2008</b> , 1, 406-12	99
1440	Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. <b>2008</b> , 68, 1105-13	14
1439	Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. <b>2008</b> , 7, 33-43	46
1438	Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. <b>2008</b> , 9, 92-101	22
1437	New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2. <b>2008</b> , 9, 326-30	2
1436	The role of targeting mammalian target of rapamycin in lung cancer. <b>2008</b> , 9, 340-5	38
1435	Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. <b>2008</b> , 9, 346-51	18
1434	Unmet need in lung cancer: can vaccines bridge the gap?. <b>2008</b> , 9 Suppl 1, S6-12	6

1433	Targeted therapies in non-small-cell lung cancer: a paradigm in evolution. <b>2008</b> , 9 Suppl 3, S90-1	1
1432	Multitargeted inhibitors in lung cancer: new clinical data. <b>2008</b> , 9 Suppl 3, S92-9	6
1431	[Acneiforme rash in woman with pulmonary adenocarcinoma]. <b>2008</b> , 208, 251-2	
1430	Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience. <b>2008</b> , 31, 11-6	9
1429	Clinical approaches to minimize rash associated with EGFR inhibitors. <b>2008</b> , 35, 103-11	17
1428	Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. <b>2008</b> , 2, 167-78	39
1427	Molecular profiling of non-small cell lung cancer: of what value in clinical practice?. <b>2008</b> , 17, 451-62	1
1426	Prolonged response to first-line erlotinib for advanced lung adenocarcinoma. <b>2008</b> , 27, 59	4
1425	EGFR Signaling Networks in Cancer Therapy. <b>2008</b> ,	7
1424	Le traitement de la rechute d'un cancer bronchique non ^petites cellules de stade IV. <b>2008</b> , 25, 3S113-3S118	
1423	Le cancer broncho-pulmonaire non ^petites cellules : point sur la pathologie et stratgie de d'cision th'apeutique. <b>2008</b> , 43, 93-102	
1422	Targeted Cancer Therapy. <b>2008</b> ,	6
1421	Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components. <b>2008</b> , 85, 216-23	10
1420	Advances in chemotherapy for non-small cell lung cancer. <b>2008</b> , 24, 49-56	4
1419	Therapeutic strategy for treatment of metastatic non-small cell lung cancer. <b>2008</b> , 42, 1640-52	22
1418	EGFR antagonists in cancer treatment. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 1160-74	59.2 1570
1417	Lung cancer. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1367-80	59.2 1920
1416	Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. <b>2008</b> , 44, 419-26	32

1415	Lifestyle habits as a contributor to anti-cancer treatment failure. <b>2008</b> , 44, 374-82	19
1414	Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21. <b>2008</b> , 29, 527-36	13
1413	Molecular-targeted therapies: lessons from years of clinical development. <b>2008</b> , 34, 61-80	41
1412	Advances in the treatment of non-small cell lung cancer. <b>2008</b> , 34, 521-6	6
1411	An overview of adjuvant chemotherapy for resected non-small cell lung cancer: focus on the ECOG 1505 phase III trial. <b>2008</b> , 5, 457-463	1
1410	Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. <b>2008</b> , 60 Suppl 2, S3-9	61
1409	Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. <b>2008</b> , 60 Suppl 2, S10-8	16
1408	The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations. <b>2008</b> , 60 Suppl 2, S19-22	17
1407	EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. <b>2008</b> , 60 Suppl 2, S23-30	42
1406	KRAS mutational testing in the selection of patients for EGFR-targeted therapies. <b>2008</b> , 25, 288-94	13
1405	Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor. <b>2008</b> , 20, 217-23	9
1404	Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. <b>2008</b> , 26, 4268-75	600
1403	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. <b>2008</b> , 26, 2442-9	725
1402	Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. <b>2008</b> , 19, 739-45	32
1401	Gefitinib or docetaxel in advanced non-small-cell lung cancer. <b>2008</b> , 372, 1785-6	5
1400	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. <b>2008</b> , 372, 1809-18	1067
1399	Lack of somatic ErbB2 tyrosine kinase domain mutations in hepatocellular carcinoma. <b>2008</b> , 38, 838-41	6
1398	Aurora kinases as anticancer drug targets. <b>2008</b> , 14, 1639-48	329

1397	Molecular genetics of lung cancer in people who have never smoked. <b>2008</b> , 9, 676-82	100
1396	Role of comprehensive cancer centres during economic and disease transition: National Cancer Centre, Singapore--a case study. <b>2008</b> , 9, 796-802	3
1395	Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. <b>2008</b> , 9, 1135-42	65
1394	An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. <b>2008</b> , 14, 803-827	20
1393	Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. <b>2008</b> , 26, 103-19, ix	39
1392	[Targeted therapies. New hopes, new challenges]. <b>2008</b> , 25, 661-2	
1391	Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement. <b>2008</b> , 18, 403-15	26
1390	Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. <b>2008</b> , 26, 121-59, ix	23
1389	KRAS mutations: an old oncogene becomes a new predictive biomarker. <b>2008</b> , 10, 493-5	41
1388	Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. <b>2008</b> , 10, 489-500	33
1387	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <b>2008</b> , 14, 2895-9	576
1386	[Bronchial carcinoma and intensive care]. <b>2008</b> , 64, 250-6	4
1385	[Management of targeted molecular therapies toxicities in thoracic cancerology]. <b>2008</b> , 64, 104-10	1
1384	[Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer]. <b>2008</b> , 25, 1096-103	7
1383	Targeted therapy for solid tumors: current status. <b>2008</b> , 17, 279-301, vii-viii	10
1382	[Efficacy and tolerance of bevacizumab in non-small cell lung cancer: preliminary report]. <b>2008</b> , 64, 166-72	
1381	Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. <b>2008</b> , 59, 227-31	12
1380	[How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study]. <b>2008</b> , 25, 91-6	4

1379	Combined anti-proliferative and anti-angiogenic strategies for cancer. <b>2008</b> , 9, 701-15	14
1378	EGFR inhibitor-associated acneiform folliculitis: assessment and management. <b>2008</b> , 9, 285-94	23
1377	EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. <b>2008</b> , 59, 429-42	120
1376	Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?. <b>2008</b> , 9, 1321-37	3
1375	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. <b>2008</b> , 26, 1626-34	2666
1374	Structure and clinical relevance of the epidermal growth factor receptor in human cancer. <b>2008</b> , 26, 1742-51	209
1373	Development of therapeutic approaches to 'triple negative' phenotype breast cancer. <b>2008</b> , 12, 1123-37	16
1372	Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. <b>2008</b> , 7, 4651-8	37
1371	Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. <b>2008</b> , 10, 160-8	45
1370	Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. <b>2008</b> , 26, 2450-6	467
1369	Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. <b>2008</b> , 26, 5407-15	198
1368	Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. <b>2008</b> , 26, 863-9	149
1367	Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth. <b>2008</b> , 100, 1606-29	63
1366	Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. <b>2008</b> , 19, 1624-8	42
1365	Challenges treating older non-small cell lung cancer patients. <b>2008</b> , 19 Suppl 7, vii109-13	9
1364	Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. <b>2008</b> , 14, 1478-86	85
1363	Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. <b>2008</b> , 19 Suppl 2, ii39-40	55
1362	Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients. <b>2008</b> , 14, 2363-70	45

1361	The role of chemotherapy at the end of life: "when is enough, enough?". <b>2008</b> , 299, 2667-78	197
1360	Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. <b>2008</b> , 14, 6317-23	53
1359	Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. <b>2008</b> , 13, 1166-76	39
1358	Target specificity and off-target effects as determinants of cancer drug efficacy. <b>2008</b> , 4, 273-80	21
1357	Gefitinib: a consideration of cost. <b>2008</b> , 8, 223-32	
1356	Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. <b>2008</b> , 13 Suppl 1, 37-46	38
1355	Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?. <b>2008</b> , 13, 933-44	35
1354	Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. <b>2008</b> , 13, 1207-23	65
1353	Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. <b>2008</b> , 26, 650-6	294
1352	Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. <b>2008</b> , 68, 2841-9	84
1351	Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. <b>2008</b> , 14, 957-60	110
1350	The use of genomics in clinical trial design. <b>2008</b> , 14, 5984-93	147
1349	Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer. <b>2008</b> , 14, 6324-9	37
1348	Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. <b>2008</b> , 14, 6867-76	40
1347	Suppression of proHB-EGF carboxy-terminal fragment nuclear translocation: a new molecular target therapy for gastric cancer. <b>2008</b> , 14, 3956-65	26
1346	Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. <b>2008</b> , 19, 2039-42	65
1345	Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia. <b>2008</b> , 1, 100-11	47
1344	Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study. <b>2008</b> , 3, 258-64	48



1343	Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. <b>2008</b> , 3, 745-50	25
1342	Predictive tests for individualization of pharmacological cancer treatment. <b>2008</b> , 2, 349-60	13
1341	Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy. <b>2008</b> , 3, 1032-8	6
1340	Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <b>2008</b> , 3, S146-9	56
1339	The effect of FDG-PET on the stage distribution of non-small cell lung cancer. <b>2008</b> , 3, 135-9	45
1338	Targeting growth factors in lung cancer. <b>2008</b> , 133, 1209-16	28
1337	The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. <b>2008</b> , 3, 1468-81	171
1336	Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports. <b>2008</b> , 31, 123-6	10
1335	Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. <b>2008</b> , 3, 117-24	41
1334	Toxicity of targeted therapies in elderly patients. <b>2008</b> , 8, 1965-76	4
1333	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. <b>2008</b> , 14, 6456-68	241
1332	Design and endpoints of clinical trials in hepatocellular carcinoma. <b>2008</b> , 100, 698-711	1360
1331	Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. <b>2008</b> , 19, 362-9	212
1330	Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. <b>2008</b> , 73, 1290-300	130
1329	Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. <b>2008</b> , 26, 4244-52	327
1328	Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. <b>2008</b> , 98, 154-60	90
1327	A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. <b>2008</b> , 98, 1774-80	41
1326	The role of gefitinib in the management of Asian patients with non-small cell lung cancer. <b>2008</b> , 17, 401-11	10

1325	Mechanisms of Disease: signal transduction in lung carcinogenesis -- a comparison of smokers and never-smokers. <b>2008</b> , 5, 610-8	19
1324	Radiologic measurements of tumor response to treatment: practical approaches and limitations. <b>2008</b> , 28, 329-44	187
1323	Bilateral eardrum perforation after long-term treatment with erlotinib. <b>2008</b> , 26, 2582-4	7
1322	In Reply. <b>2008</b> , 26, 4850-4851	1
1321	Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. <b>2008</b> , 14, 6963-73	106
1320	Considerations for second-line therapy of non-small cell lung cancer. <b>2008</b> , 13 Suppl 1, 28-36	90
1319	Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. <b>2008</b> , 19, 185-90	16
1318	Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. <b>2008</b> , 14, 4943-50	55
1317	18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer. <b>2008</b> , 14, 2036-41	39
1316	Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. <b>2008</b> , 13 Suppl 1, 5-13	262
1315	Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. <b>2008</b> , 26, 1135-41	63
1314	Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. <b>2008</b> , 180, 4338-45	20
1313	SPIKE\$: a six-step protocol for delivering bad news about the cost of medical care. <b>2008</b> , 26, 4200-4	33
1312	Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?. <b>2008</b> , 14, 3860-6	47
1311	Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. <b>2008</b> , 26, 3351-7	249
1310	Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. <b>2008</b> , 26, 897-906	91
1309	A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. <b>2008</b> , 19, 86-91	60
1308	Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. <b>2008</b> , 26, 4319-25	115

1307	Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective. <b>2008</b> , 11, 383-96	10
1306	Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. <b>2008</b> , 19, 787-92	74
1305	Principles of Molecular Oncology. <b>2008</b> ,	1
1304	ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. <b>2008</b> , 14, 3291-8	25
1303	EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis. <b>2008</b> , 294, L1217-25	71
1302	Handling side-effects of targeted therapies: safety of targeted therapies in solid tumours. <b>2008</b> , 19 Suppl 7, vii146-52	8
1301	Nursing management of epidermal growth factor receptor inhibitor-induced toxicities. <b>2008</b> , 12, 405-7	4
1300	Updates in non-small cell lung cancer. <b>2008</b> , 12, 587-96	42
1299	Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. <b>2008</b> , 26, 983-94	253
1298	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. <b>2008</b> , 26, 2745-53	222
1297	The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). <b>2008</b> , 14, 5685-91	8
1296	Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. <b>2008</b> , 13, 1201-4	27
1295	Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. <b>2008</b> , 14, 4326-35	26
1294	Carcinoma of the bronchus 60 years later. <b>2006</b> , 61, 1023-8	4
1293	The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. <b>2008</b> , 7, 1251-7	30
1292	EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. <b>2009</b> , 33, 436-40	33
1291	Small Molecules: Big Changes in the Cancer Treatment Paradigm. <b>2008</b> , 21, 17-35	1
1290	Systemic treatment for advanced (stage IIIB/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. <b>2008</b> , 13 Suppl 1, 1-4	18

1289	Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. <b>2008</b> , 13 Suppl 1, 14-20	67
1288	A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. <b>2008</b> , 14, 3867-74	70
1287	Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. <b>2008</b> , 26, 2350-7	186
1286	Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry. <b>2008</b> , 36, 133-9	15
1285	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. <b>2008</b> , 14, 7060-7	135
1284	What's new in oncology: targeted therapy. <b>2008</b> , 8, 36-38	
1283	A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. <b>2008</b> , 129, 202-10	41
1282	The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. <b>2008</b> , 14, 2088-94	44
1281	Novel strategies for the treatment of lung cancer: modulation of eicosanoids. <b>2008</b> , 26, 825-7	6
1280	Proteomic contributions to personalized cancer care. <b>2008</b> , 7, 1780-94	77
1279	A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. <b>2008</b> , 14, 7878-83	95
1278	Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. <b>2008</b> , 68, 3314-22	113
1277	First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology?. <b>2008</b> , 26, 3485-6	47
1276	MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. <b>2008</b> , 3, 331-9	168
1275	Newer opportunities in systemic therapy of lung cancer. <b>2008</b> , 19 Suppl 7, vii31-7	5
1274	Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. <b>2009</b> , 39, 27-32	32
1273	Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptor L858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. <b>2008</b> , 74, 793-806	46
1272	EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. <b>2008</b> , 26, 5589-95	180

1271	In Reply. <b>2008</b> , 26, 1184-1186	21
1270	Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. <b>2008</b> , 26, 1871-8	111
1269	A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. <b>2008</b> , 19, 332-9	24
1268	Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. <b>2008</b> , 26, 5972-9	27
1267	Second-Line-Therapie des nichtkleinzelligen Lungenkarzinoms (NSCLC) –eine retrospektive Kostenanalyse. <b>2008</b> , 29, 211-217	2
1266	Avaliação econômica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmã de cã pequenas cãulas. <b>2008</b> , 14, 803-827	9
1265	Targeting blood vessels for the treatment of non-small cell lung cancer. <b>2008</b> , 8, 392-403	9
1264	Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. <b>2008</b> , 5, 268-78	77
1263	Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology. <b>2008</b> , 17, 1013-28	41
1262	Somatic pharmacogenomics in cancer. <b>2008</b> , 8, 305-14	21
1261	Medikamentöse Therapie des kleinzelligen Bronchialkarzinoms (SCLC) - neue molekulare Therapieansätze. <b>2008</b> , 29, 81-90	
1260	Radiofrequency ablation of pulmonary malignancies. <b>2008</b> , 29, 361-83	20
1259	Complications of lung cancer treatment. <b>2008</b> , 29, 302-17	19
1258	[Drug therapy for small-cell lung cancer (SCLC)--new molecular strategies for therapy]. <b>2008</b> , 62, 23-30	1
1257	Targeted therapy in advanced non-small-cell lung cancer. <b>2008</b> , 29, 291-301	24
1256	Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. <b>2008</b> , 5, 487-91	50
1255	From nihilism to individualism: the evolution of lung cancer therapy. <b>2008</b> , 177, 1299-300	2
1254	Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time. <b>2008</b> , 26, 2426-7	12

- 1253 Lung cancer treatment - Biology based decision, from gene to histology. **2008**, 14 Suppl 2, S27-34 2
- 1252 Erlotinib: An EGFR inhibitor with therapeutic benefit in non-small cell lung cancer. **2008**, 14 Suppl 3, S5-6
- 1251 Erlotinib in second-line therapy for non-small cell lung cancer - A clinical case. **2008**, 14 Suppl 3, S17-22 0
- 1250 Erlotinib and brain metastases. **2008**, 14 Suppl 3, S35-42 1
- 1249 Treatment of non-small cell lung cancer, advanced disease, with erlotinib in 2(nd) and 3(rd) lines. Two cases report. **2008**, 14 Suppl 3, S53-60
- 1248 Erlotinib as an alternative treatment for NSCLC. Case Report. **2008**, 14 Suppl 3, S61-4
- 1247 Non-small cell lung cancer patients treated with erlotinib - Clinical cases. **2008**, 14 Suppl 3, S65-70
- 1246 Long survival with erlotinib as second line treatment in non-small cell lung cancer. **2008**, 14 Suppl 3, S85-8
- 1245 Lung cancer and women. **2008**, 4, 705-16 12
- 1244 Long-lasting control with erlotinib in advanced non-small cell lung cancer (NSCLC). **2008**, 14 Suppl 3, S9-S15 0
- 1243 Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. **2008**, 2, 577-586 24
- 1242 Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. **2008**, 7, 599-606 59
- 1241 Current status of antivasular therapy and targeted treatment in the clinic. **2008**, 24, 97-110 0
- 1240 Vinflunine: clinical perspectives of an emerging anticancer agent. **2008**, 17, 583-91 18
- 1239 The potential role of mTOR inhibitors in non-small cell lung cancer. **2008**, 13, 139-47 98
- 1238 Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥70 Years of Age Treated With Erlotinib for Advanced Non-Small-Cell Lung Cancer. **2008**, 2008, 185-186
- 1237 A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. **2008**, 3, 631-6 65
- 1236 Overview of clinical trials for lung cancer in the elderly. **2008**, 4, 629-642

1235	Second-line treatment of advanced non-small cell lung cancer. <b>2008</b> , 3, 430-40	52
1234	Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. <b>2008</b> , 3, 1446-53	86
1233	Pulmonary complications of novel antineoplastic agents for solid tumors. <b>2008</b> , 133, 528-38	185
1232	Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene. <b>2008</b> , 3, 643-7	17
1231	The current status and evolving role of sunitinib in non-small cell lung cancer. <b>2008</b> , 3, S119-23	23
1230	EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer. <b>2008</b> , 3, 303-10	33
1229	First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients. <b>2008</b> , 3, S143-5	19
1228	Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. <b>2008</b> , 3, 1286-92	41
1227	Pulmonary epithelioid haemangioendothelioma and bevacizumab. <b>2008</b> , 3, 557-8	44
1226	A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. <b>2008</b> , 3, 386-93	78
1225	Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: A methodological challenge and an ongoing debate on the clinical relevance. <b>2008</b> ,	1
1224	Reducing the NHS cancer drugs bill. <b>2008</b> , 7, 6-7	
1223	Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. <b>2008</b> , 3, 664-73	31
1222	Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. <b>2008</b> , 3, 832-9	115
1221	Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum. <b>2008</b> , 3, 637-42	3
1220	A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. <b>2008</b> , 3, 590-8	44
1219	Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. <b>2008</b> , 3, 1026-31	34
1218	Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation. <b>2008</b> , 3, 451-2	11

1217	Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study. <b>2008</b> , 3, 887-93	22
1216	Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective. <b>2008</b> , 11, 363-66; author reply 366-70	3
1215	Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. <b>2008</b> , 3, 1439-45	67
1214	Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. <b>2008</b> , 3, 1104-11	29
1213	A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. <b>2008</b> , 3, 1153-8	30
1212	Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. <b>2008</b> , 3, 84-93	24
1211	Cytostatic and cytotoxic drugs. <b>2008</b> , 520-532	1
1210	First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view. <b>2008</b> , 2 Suppl 2, S3	10
1209	Conclusions of the expert panel: importance of erlotinib as a second-line therapeutic option. <b>2008</b> , 2 Suppl 2, S4	1
1208	Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer. <b>2008</b> , 3, 234-243	
1207	Principe des mécanismes d'action des thérapeutiques moléculaires ciblées en cancérologie pulmonaire. <b>2008</b> , 5, 1-16	
1206	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. <b>2008</b> , 2008, 138-140	
1205	Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. <b>2008</b> , 3, 1050-3	19
1204	Targeted therapy for advanced renal cell cancer: cytokines and beyond. <b>2008</b> , 14, 2229-51	11
1203	Erlotinib in non-small cell lung cancer's second line treatment. Clinical case. <b>2008</b> , 14 Suppl 3, S79-83	
1202	Gefitinib-associated <i>Propionibacterium acnes</i> pleural empyema. <b>2008</b> , 3, 556-7	6
1201	Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer. <b>2008</b> , 3, 400-4	53
1200	Phase I/II study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer. <b>2008</b> , 3, 1012-7	16



1199	Molecular analysis-based treatment strategies for non-small cell lung cancer. <b>2008</b> , 15, 130-9	19
1198	First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. <b>2008</b> , 3, S138-42	7
1197	Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. <b>2008</b> , 3, 912-4	36
1196	Epidemiology, Diagnosis, Staging and the Medical-Surgical Management of Lung Cancers. 424-439	
1195	Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. <b>2008</b> , 3, 1003-11	54
1194	Invited Speakers Abstracts. <b>2008</b> , 3, S179-S204	
1193	New directions in the management of advanced pancreatic cancer: a review. <b>2008</b> , 19, 435-46	32
1192	Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. <b>2008</b> , 19, 209-16	68
1191	A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naïve malignancies. <b>2008</b> , 14, 1131-7	16
1190	SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2. <b>2008</b> , 19, 9-16	13
1189	Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. <b>2008</b> , 20, 162-75	39
1188	Targeted therapy developments in the treatment of non-small cell lung cancer: a promising but long and winding road. <b>2008</b> , 20, 145-7	5
1187	Advances in the Treatment of Metastatic Non-Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. <b>2008</b> , 15, 352-358	
1186	Cell signaling modifiers in prostate cancer. <b>2008</b> , 14, 40-5	7
1185	Lung. 313-327	
1184	EGFR-targeted therapeutics: focus on SCCHN and NSCLC. <b>2008</b> , 8, 909-19	19
1183	The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada. <b>2008</b> , 15, 136-42	33
1182	Adjuvant chemotherapy for lung cancer: cisplatin doublets only?. <b>2008</b> , 6, 277-84	2

1181	The role of inhibitors of the epidermal growth factor in management of head and neck cancer. <b>2008</b> , 6, 696-706	11
1180	Erlotinib in Advanced Well-Differentiated Thymic Carcinoma with Overexpression of EGFR: A Case Report. <b>2008</b> , 94, 849-852	9
1179	Molecularly Targeted Therapy for Lung Cancer: Recent Topics. <b>2008</b> , 7, 1	2
1178	New insights in drug development for the non-small cell lung cancer therapy. <b>2008</b> , 13, 5108-19	4
1177	Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. <b>2008</b> , 5, 209-17	57
1176	Tumor-associated EGFR over-expression specifically activates Stat3 and Smad7 resulting in desensitization of TGF- $\beta$ signaling. <b>2008</b> ,	1
1175	Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. <b>2008</b> , 15, 279-85	39
1174	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. <b>2009</b> , 215	
1173	A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. <b>2009</b> , 19, 929-33	78
1172	7 Lungenkrebsvorsorge bei Rauchern. <b>2009</b> ,	
1171	Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed. <b>2009</b> , 2, 21-37	
1170	Treatment of advanced non small cell lung cancer in routine care: a retrospective analysis of 212 consecutive patients treated in a community based oncology group practice. <b>2009</b> , 3, 63-70	1
1169	Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC). <b>2009</b> , 8, 61	
1168	Efficacy and Safety of Pemetrexed in Advanced Non-Small Cell Lung Carcinoma. <b>2009</b> , 67, 121	
1167	[Targeting HER pathway in head and neck and thoracic cancers]. <b>2009</b> , 96 Suppl 1, S35-43	
1166	[Targeting of the AKT-mTOR pathway in head and neck and lung cancer]. <b>2009</b> , 96 Suppl 1, S57-63	
1165	Efficacy of Pemetrexed in Relapsed Non-Small Cell Lung Cancer and Thymidylate Synthase Expression. <b>2009</b> , 67, 191	5
1164	Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung. <b>2009</b> , 24, 448-52	50

1163	[Information on head, neck and lung cancers]. <b>2009</b> , 96 Suppl 1, S5-11	
1162	[Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value]. <b>2009</b> , 96 Suppl, S57-68	1
1161	[KRAS status versus EGFR status in lung cancer therapy]. <b>2009</b> , 96 Suppl, S75-83	1
1160	[Radiotherapy and targeted therapies in non-small-cell lung cancer]. <b>2009</b> , 96, 311-9	0
1159	Optimizing the management of advanced non-small-cell lung cancer: a personal view. <b>2009</b> , 16, 9-21	28
1158	Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. <b>2009</b> , 2009, 567486	85
1157	Gemcitabine for the treatment of advanced nonsmall cell lung cancer. <b>2009</b> , 2, 209-17	12
1156	Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature. <b>2009</b> , 4, 27-33	7
1155	The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement. <b>2009</b> , 16, 27-48	19
1154	Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis. <b>2009</b> , 4, 988-93	3
1153	Lung cancer: current diagnosis and treatment. <b>2009</b> , 106, 809-18; quiz 819-20	46
1152	Bevacizumab: Its Place in the Treatment of Advanced Non-small Cell Lung Cancer. <b>2009</b> , 1, CMT.S1949	
1151	Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib. <b>2009</b> , 1, CMT.S2122	
1150	Small-molecule inhibitors of the human epidermal receptor family. <b>2009</b> , 18, 1829-42	23
1149	Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence. <b>2009</b> , 9, 409-16	12
1148	Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. <b>2009</b> , 296, C954-76	122
1147	A review of in vitro and in vivo models of oesophageal and gastric cancer. <b>2009</b> , 4, 1267-79	
1146	Micropapillary histology: a frequent morphology of mutation-associated lung adenocarcinoma?. <b>2009</b> , 131, 615-7	6

1145	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. <b>2009</b> , 15, 5267-73	328
1144	A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. <b>2009</b> , 106, 16996-7001	218
1143	Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. <b>2009</b> , 27, 5620-6	76
1142	The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. <b>2009</b> , 27, 1350-4	56
1141	Integration of molecular profiling into the lung cancer clinic. <b>2009</b> , 15, 5317-22	73
1140	Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. <b>2009</b> , 14, 119-24	18
1139	A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. <b>2009</b> , 101, 1453-63	88
1138	Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. <b>2009</b> , 18, 1735-51	52
1137	Radiochemotherapy in the elderly with lung cancer. <b>2009</b> , 9, 1405-11	8
1136	A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. <b>2009</b> , 17, 206-18	78
1135	Erlotinib: applications in therapy and current status of research. <b>2009</b> , 2, 15-36	1
1134	Emerging therapeutic targets in non-small cell lung cancer. <b>2009</b> , 6, 218-23	16
1133	Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. <b>2009</b> , 15, 6639-48	95
1132	Targeted therapy: comprehensive review. <b>2009</b> , 26, 137-46	5
1131	A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. <b>2009</b> , 4, 214-9	18
1130	Combination of radiotherapy and chemotherapy in locally advanced NSCLC. <b>2009</b> , 9, 1389-403	9
1129	Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. <b>2009</b> , 14, 399-411	76
1128	Lessons from gefitinib-induced interstitial lung disease: Pharmacovigilance for erlotinib in Japan. <b>2009</b> , 21, 161-167	

1127	Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. <b>2009</b> , 20, 1674-81	134
1126	Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer. <b>2009</b> , 1, 137-44	17
1125	A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). <b>2009</b> , 20, 1068-73	29
1124	The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. <b>2009</b> , 20, 1257-63	14
1123	Mechanisms of tumor resistance to EGFR-targeted therapies. <b>2009</b> , 13, 339-62	66
1122	Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. <b>2009</b> , 27, 4274-80	169
1121	Current treatments for advanced stage non-small cell lung cancer. <b>2009</b> , 6, 233-41	113
1120	Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?. <b>2009</b> , 7, 1000-12	93
1119	EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. <b>2009</b> , 62, 970-7	94
1118	Lung cancer in women: the differences in epidemiology, biology and treatment outcomes. <b>2009</b> , 3, 627-34	15
1117	Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. <b>2009</b> , 20, 1455-1457	3
1116	Positron emission tomography (PET) imaging with [ <sup>11</sup> C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. <b>2009</b> , 69, 873-8	135
1115	Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. <b>2009</b> , 69, 5091-8	52
1114	Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. <b>2009</b> , 69, 6694-703	142
1113	Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California. <b>2009</b> , 18, 2248-55	17
1112	Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. <b>2009</b> , 15, 907-13	44
1111	Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. <b>2009</b> , 15, 5040-8	22
1110	Angiogenesis inhibitors in the treatment of non-small cell lung cancer. <b>2009</b> , 1, 95-107	6

1109	Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. <b>2009</b> , 27, 5255-61	205
1108	Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter? A single-institution experience. <b>2009</b> , 76, 85-90	8
1107	[Response judgement - conventional versus new methods]. <b>2009</b> , 32 Suppl 1, 9-17	2
1106	Biological prognostic and predictive factors in lung cancer. <b>2009</b> , 77 Suppl 1, 90-6	24
1105	Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option?. <b>2009</b> , 77 Suppl 1, 113-21	73
1104	Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study. <b>2009</b> , 76, 112-7	28
1103	Systemic therapies in hepatocellular carcinoma. <b>2009</b> , 27, 175-88	50
1102	Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype. <b>2009</b> , 19, 629-37	9
1101	Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. <b>2009</b> , 4, S1029-39; quiz S1041-2	36
1100	Ras-MAPK pathway as a therapeutic target in cancer--emphasis on bladder cancer. <b>2009</b> , 4, 125-36	35
1099	Adjuvant therapy for resected non-small cell lung cancer. <b>2009</b> , 1, 109-18	6
1098	Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. <b>2009</b> , 4, 689-96	24
1097	Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. <b>2009</b> , 1, 590-9	5
1096	EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. <b>2009</b> , 4, 1466-72	59
1095	Advances in personalized therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivity. <b>2009</b> , 8, 2051-3	3
1094	Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. <b>2009</b> , 135, 1596-1609	30
1093	Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. <b>2009</b> , 4, 586-94	16
1092	Targeted therapies in lung cancer. <b>2009</b> , 15, 188-206	33

1091	The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. <b>2009</b> , 9, 703-15		34
1090	Arab A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803-827. <b>2009</b> , 15, 560-6		
1089	Personalized medicine and inhibition of EGFR signaling in lung cancer. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 1018-20	59.2	146
1088	Angiogenesis in the treatment of non-small cell lung cancer. <b>2009</b> , 6, 206-17		24
1087	Modular protein engineering in emerging cancer therapies. <b>2009</b> , 15, 893-916		31
1086	Targeting the eicosanoid pathway in non-small-cell lung cancer. <b>2009</b> , 13, 675-88		12
1085	New avenues for second-line treatment of metastatic non-small-cell lung cancer. <b>2009</b> , 9, 115-24		9
1084	New Agents âManifold Consequences: The Management of Lung and Colorectal Cancer is Changing. <b>2009</b> , 5, 1-19		
1083	What's positive about 'triple-negative' breast cancer?. <b>2009</b> , 5, 1015-25		19
1082	Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. <b>2009</b> , 8, 497-502		18
1081	MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC. <b>2009</b> , 8, 522-30		30
1080	Role of tyrosine kinase inhibitors in lung cancer. <b>2009</b> , 9, 569-75		24
1079	Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. <b>2009</b> , 10, 470-81		388
1078	Cancer stem cells: the emerging challenge of drug targeting. <b>2009</b> , 16, 394-416		50
1077	Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. <b>2009</b> , 6, 287-94		19
1076	Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. <b>2009</b> , 8, 1536-46		23
1075	A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. <b>2009</b> , 20, 1074-9		85
1074	Clinical trial designs for predictive biomarker validation: one size does not fit all. <b>2009</b> , 19, 530-42		92

1073	Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. <b>2009</b> , 4, e4576	154
1072	Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. <b>2009</b> , 27, 1220-6	115
1071	Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells. <b>2009</b> , 7, 1378-89	42
1070	The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. <b>2009</b> , 15, 4885-94	91
1069	Crescentic glomerulonephritis in a patient with advanced lung cancer during erlotinib therapy. <b>2009</b> , 2, 512-3	5
1068	How far do you go? Efficient searching for indirect evidence. <b>2009</b> , 29, 273-81	26
1067	EGFR-targeted therapies in lung cancer: predictors of response and toxicity. <b>2009</b> , 10, 59-68	54
1066	ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). <b>2009</b> , 20, 689-95	33
1065	The role of EGFR inhibition in the treatment of non-small cell lung cancer. <b>2009</b> , 14, 1116-30	44
1064	Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. <b>2009</b> , 27, 4481-6	198
1063	A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. <b>2009</b> , 15, 2552-8	230
1062	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. <b>2009</b> , 15, 7502-7509	115
1061	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. <b>2009</b> , 15, 3484-94	244
1060	The Role of Chemotherapy in the Treatment of Bone Metastases. <b>2009</b> , 287-298	5
1059	Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. <b>2009</b> , 27, 5868-73	75
1058	Who's assessing tobacco use in cancer clinical trials?. <b>2009</b> , 11, 1354-8	5
1057	Lung cancer in never smokers: molecular profiles and therapeutic implications. <b>2009</b> , 15, 5646-61	122
1056	Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. <b>2009</b> , 27, 5650-9	103



1055	EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. <b>2009</b> , 131, 478-89	64
1054	Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. <b>2009</b> , 15, 4806-14	154
1053	A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. <b>2009</b> , 18, 11-21	86
1052	Five strategies for accelerating the war on cancer in an era of budget deficits. <b>2009</b> , 14, 110-6	3
1051	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. <b>2009</b> , 20, 213-26	31
1050	Alternate endpoints for screening phase II studies. <b>2009</b> , 15, 1873-82	68
1049	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. <b>2009</b> , 20, 696-702	161
1048	Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. <b>2009</b> , 15, 256-66	82
1047	Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. <b>2009</b> , 43, 542-5	18
1046	A case of bullous dermatitis induced by erlotinib. <b>2009</b> , 14, 1201-4	4
1045	Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. <b>2009</b> , 14, 840-7	31
1044	Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. <b>2009</b> , 15, 4493-8	159
1043	Pathogenesis of lung cancer signalling pathways: roadmap for therapies. <b>2009</b> , 33, 1485-97	114
1042	Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. <b>2009</b> , 20 Suppl 4, 68-70	107
1041	Analysis of ErbB receptors in pulmonary carcinoid tumors. <b>2009</b> , 15, 3315-24	41
1040	CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. <b>2009</b> , 9, 213	27
1039	Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study. <b>2009</b> , 9, 333	34
1038	Novel agents on the horizon for cancer therapy. <b>2009</b> , 59, 111-37	241

1037	Targeted therapy in lung cancer: the good, the bad, and the ugly. <b>2009</b> , 10, 10-2	3
1036	Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. <b>2009</b> , 10, 20-7	16
1035	Second-line therapy for non-small-cell lung cancer. <b>2009</b> , 10, 91-8	5
1034	Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management. <b>2009</b> , 10, 106-11	34
1033	Gene expression profiling and non-small-cell lung cancer: where are we now?. <b>2009</b> , 10, 168-73	14
1032	Highlights from: The 2009 Annual Meeting of the American Society of Clinical Oncology Orlando, FL May 29-June 2, 2009. <b>2009</b> , 10, 217-222	
1031	Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. <b>2009</b> , 10, 273-80	44
1030	S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer. <b>2009</b> , 10, 290-4	24
1029	Highlights From: The 13th World Conference on Lung Cancer San Francisco, CA July 31-August 4, 2009. <b>2009</b> , 10, 317-321	
1028	Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. <b>2009</b> , 10, 395-404	2
1027	Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden. <b>2009</b> , 10, 426-32	4
1026	Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. <b>2009</b> , 10 Suppl 1, S7-16	11
1025	Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. <b>2009</b> , 10 Suppl 1, S17-23	10
1024	Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer. <b>2009</b> , 10 Suppl 1, S24-9	4
1023	[Lung cancer in Spain. Current epidemiology, survival, and treatment]. <b>2009</b> , 45, 341-8	28
1022	Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. <b>2009</b> , 625, 6-22	18
1021	Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. <b>2009</b> , 10, 13-19	
1020	The role of intra-cerebrospinal fluid treatment and prophylaxis in patients with solid tumors. <b>2009</b> , 36, S55-68	8

1019	Lung cancer outcomes in women. <b>2009</b> , 36, 532-41	13
1018	Introduction: women and lung cancer. <b>2009</b> , 36, 504-5	
1017	Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women. <b>2009</b> , 36, 572-80	41
1016	Menopausal hormone therapy, hormone receptor status, and lung cancer in women. <b>2009</b> , 36, 566-71	21
1015	Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. <b>2009</b> , 124, 2744-9	39
1014	Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. <b>2009</b> , 125, 1728-34	22
1013	EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. <b>2009</b> , 125, 2479-82	83
1012	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. <b>2009</b> , 115, 616-23	359
1011	A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. <b>2009</b> , 115, 1713-22	31
1010	Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. <b>2009</b> , 115, 1518-30	18
1009	Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. <b>2009</b> , 115, 2165-76	65
1008	Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. <b>2009</b> , 115, 3571-80	76
1007	Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm. <b>2009</b> , 115, 5143-54	23
1006	Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. <b>2009</b> , 115, 5516-25	54
1005	Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. <b>2009</b> , 135, 467-76	9
1004	EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. <b>2009</b> , 135, 771-82	34
1003	Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. <b>2009</b> , 135, 1483-93	22
1002	Phase I study of amrubicin and vinorelbine in non-small cell lung cancer previously treated with platinum-based chemotherapy. <b>2009</b> , 14, 125-9	1

1001	Aktuelle Entwicklungen in der Bildgebung beim nichtkleinzelligen Bronchialkarzinom. <b>2009</b> , 15, 496-501	
1000	Second and third line treatment in non-small cell lung cancer. <b>2009</b> , 71, 117-26	7
999	Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. <b>2009</b> , 115, 115-21	101
998	Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo. <b>2009</b> , 27, 1-11	7
997	Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. <b>2009</b> , 11, 428-36	4
996	Lung Cancer OncoGuia. <b>2009</b> , 11, 805-24	5
995	NSCLC in the elderly--the legacy of therapeutic neglect. <b>2009</b> , 10, 180-94	9
994	Abstracts 2009. <b>2009</b> , 10, 1-213	
993	Translating genomics into clinical practice: applications in lung cancer. <b>2009</b> , 11, 263-8	5
992	Investigational agents in the management of non-small cell lung cancer. <b>2009</b> , 11, 275-84	4
991	Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer. <b>2009</b> , 4, 37-44	11
990	Renal toxicity of targeted therapies. <b>2009</b> , 4, 121-33	41
989	Skin toxicities associated with epidermal growth factor receptor inhibitors. <b>2009</b> , 4, 107-19	218
988	Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. <b>2009</b> , 4, 267-73	19
987	Tyrosinkinaseinhibitoren beim nichtkleinzelligen Lungenkarzinom. <b>2009</b> , 2, 80-85	
986	Molecular markers and pathogenically targeted therapy in non-small cell lung cancer. <b>2009</b> , 3, 245-255	1
985	[Hemorrhagic pericardial effusion and multiple pulmonary nodules in a 37 year old male who has "never smoked"]. <b>2009</b> , 50, 91-4	2
984	Respiration-averaged CT for attenuation correction in non-small-cell lung cancer. <b>2009</b> , 36, 607-15	16

983	A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. <b>2009</b> , 64, 379-84	9
982	Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. <b>2009</b> , 64, 539-48	47
981	Erlotinib in advanced non-small-cell lung cancer after gefitinib failure. <b>2009</b> , 64, 1123-7	22
980	A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. <b>2009</b> , 64, 1181-5	28
979	Reinforcement learning design for cancer clinical trials. <b>2009</b> , 28, 3294-315	130
978	Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. <b>2009</b> , 100, 1526-31	11
977	Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. <b>2009</b> , 100, 2054-9	75
976	Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. <b>2009</b> , 161, 515-21	94
975	Three cases of severe hepatic impairment caused by erlotinib. <b>2009</b> , 68, 464-7	10
974	Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. <b>2009</b> , 86, 167-74	166
973	A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. <b>2009</b> , 22, 1032-43	80
972	Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. <b>2009</b> , 9, 321-6	143
971	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. <b>2009</b> , 6, 352-66	178
970	Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. <b>2009</b> , 8, 709-23	259
969	The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC. <b>2009</b> , 28 Suppl 1, S1-3	5
968	Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. <b>2009</b> , 28 Suppl 1, S4-13	56
967	Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. <b>2009</b> , 28 Suppl 1, S14-23	163
966	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. <b>2009</b> , 28 Suppl 1, S24-31	636

965	Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. <b>2009</b> , 28 Suppl 1, S38-45	25
964	Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. <b>2009</b> , 101, 1543-8	117
963	EGFR mutation testing in NSCLC: Patterns of care and outcomes in Western Australia. <b>2009</b> , 5, 66-71	3
962	Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer. <b>2009</b> , 14, 709-15	20
961	Erlotinib activates mitochondrial death pathways related to the production of reactive oxygen species in the human non-small cell lung cancer cell line A549. <b>2009</b> , 36, 487-94	16
960	Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis. <b>2009</b> , 3, 181-4	4
959	Changing healthcare practice for older adults with late-stage non-small cell lung cancer: practical considerations of targeted therapy in primary care and oncology. <b>2009</b> , 57 Suppl 2, S253-8	1
958	New drugs for the treatment of hepatocellular carcinoma. <b>2009</b> , 29 Suppl 1, 148-58	19
957	The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. <b>2009</b> , 12, 20-7	66
956	No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data. <b>2009</b> , 12, 996-1003	35
955	Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. <b>2009</b> , 21, 464-72	54
954	Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review. <b>2009</b> , 69, 223-36	7
953	Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. <b>2009</b> , 33, 73-111	17
952	Epidermal growth factor receptor inhibitors: current status and future directions. <b>2009</b> , 33, 245-94	9
951	Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. <b>2009</b> , 74, 1391-6	56
950	Cell Adhesion Molecules. <b>2009</b> , 19-28	
949	High-throughput biochemical kinase selectivity assays: panel development and screening applications. <b>2009</b> , 14, 31-42	41
948	Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma. <b>2009</b> , 16, 152-8	22

947	Lung Cancer: Overview. <b>2009</b> , 1-27	2
946	Current Clinical Management of Metastatic Lung Cancer. <b>2009</b> , 317-350	
945	Gefitinib - a potential new treatment option in lung cancer. <b>2009</b> , 10, 7-13	
944	Pharmacogenomics in non-small-cell lung cancer chemotherapy. <b>2009</b> , 61, 408-17	24
943	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. <b>2009</b> , 27, 6251-66	619
942	MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. <b>2009</b> , 106, 12085-90	423
941	Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. <b>2009</b> , 27, 6243-50	69
940	Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. <b>2009</b> , 27, 1667-74	456
939	Assessing tumor response to therapy. <b>2009</b> , 50 Suppl 1, 1S-10S	193
938	Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. <b>2009</b> , 27, 5080-7	191
937	Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. <b>2009</b> , 27, 2523-9	189
936	An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. <b>2009</b> , 20, 486-91	32
935	Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. <b>2009</b> , 27, 264-70	49
934	Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. <b>2009</b> , 35, 167-74	46
933	Management of unfit older patients with advanced NSCLC. <b>2009</b> , 35, 517-21	14
932	The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. <b>2009</b> , 12, 95-102	50
931	A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. <b>2009</b> , 45, 782-8	59
930	Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. <b>2009</b> , 45, 601-7	41

929	Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. <b>2009</b> , 45, 2316-23	70
928	Targeted therapies in the treatment of advanced/metastatic NSCLC. <b>2009</b> , 45, 2473-87	57
927	Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo. <b>2009</b> , 279, 213-20	13
926	Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. <b>2009</b> , 281, 134-43	13
925	[State of the art in chemoradiotherapy combinations and potential role in targeting therapy approaches in nonsmall cell lung cancer]. <b>2009</b> , 13, 114-22	1
924	Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. <b>2009</b> , 15, 326-35	24
923	Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial. <b>2009</b> , 74, 665-71	33
922	[Targeted therapies and their indications in solid neoplasias]. <b>2009</b> , 30, 416-24	4
921	Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines. <b>2009</b> , 154, 9-12	9
920	Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. <b>2009</b> , 40, 1152-8	157
919	[Diagnosis and treatment of hepatocellular carcinoma]. <b>2009</b> , 132, 272-87	37
918	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. <b>2009</b> , 27, 2653-9	237
917	Pharmacologic and chemical adjuvants in tumor virotherapy. <b>2009</b> , 109, 3125-40	41
916	Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. <b>2009</b> , 63, 1-9	32
915	Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. <b>2009</b> , 63, 219-26	177
914	Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. <b>2009</b> , 63, 418-24	41
913	Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. <b>2009</b> , 64, 51-9	70
912	Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands. <b>2009</b> , 64, 110-6	31



911	Non-small cell lung cancer-smokers or non-smokers, does it matter?. <b>2009</b> , 63, 430-2		1
910	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy. <b>2009</b> , 64, 199-206		19
909	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. <b>2009</b> , 64, 346-51		40
908	Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. <b>2009</b> , 66, 257-61		16
907	Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial. <b>2009</b> , 66, 338-43		14
906	Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study. <b>2009</b> , 66, 333-7		4
905	Pemetrexed in the treatment of advanced non-squamous lung cancer. <b>2009</b> , 66, 141-9		40
904	In vitro to in vivo concordance of a high throughput assay of bone marrow toxicity across a diverse set of drug candidates. <b>2009</b> , 188, 98-103		23
903	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 947-57	59.2	6253
902	Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer. <b>2009</b> , 20, 70-1		4
901	Lung Cancer in Spain. Current Epidemiology, Survival, and Treatment. <b>2009</b> , 45, 341-348		9
900	Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. <b>2009</b> , 10, 148-50		17
899	Advanced non-small-cell lung cancer in the elderly. <b>2009</b> , 10, 158-67		9
898	Progress in the treatment of metastatic non-small-cell lung cancer: slow but steady!. <b>2009</b> , 10, 260-1		
897	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. <b>2009</b> , 10, 281-9		330
896	Cancer treatments: can we find treasures at the bottom of the sea?. <b>2009</b> , 10, 295-300		21
895	Recent advances of novel targeted therapy in non-small cell lung cancer. <b>2009</b> , 2, 2		52
894	Gefitinib for the treatment of non-small-cell lung cancer. <b>2009</b> , 9, 17-35		35

893	EGFR-directed therapies to treat non-small-cell lung cancer. <b>2009</b> , 18, 1133-45	8
892	The epidermal growth factor receptor: a link between inflammation and liver cancer. <b>2009</b> , 234, 713-25	91
891	Basic Concepts of Molecular Pathology. <b>2009</b> ,	1
890	Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. <b>2009</b> , 27, 2038-45	125
889	Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. <b>2009</b> , 48, 578-83	109
888	Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer. <b>2009</b> , 18, 293-301	13
887	Molecular targeted therapies for solid tumors: management of side effects. <b>2009</b> , 32, 129-38	10
886	The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. <b>2009</b> , 28, 97	18
885	Targeting targeted agents: open issues for clinical trial design. <b>2009</b> , 28, 66	15
884	[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months]. <b>2009</b> , 65, 318-21	1
883	Current status and future prospects for anti-angiogenic therapies in cancer. <b>2009</b> , 4, 961-79	24
882	Chemotherapy for lung cancer: the state of the art in 2009. <b>2009</b> , 9, 1365-78	36
881	Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. <b>2009</b> , 27, 591-8	339
880	A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. <b>2010</b> , 28, 208-15	7
879	Is there a need to take ethnicity into account when considering lung cancer treatment?. <b>2009</b> , 3, 1-4	
878	Lestaurtinib: a multi-targeted FLT3 inhibitor. <b>2009</b> , 2, 17-26	12
877	Ex vivo biomarkers: functional tools to guide targeted drug development and therapy. <b>2009</b> , 9, 787-94	3
876	Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors. <b>2009</b> , 85, 943-54	34

875	Ethnic differences in drug metabolism and toxicity from chemotherapy. <b>2009</b> , 5, 243-57	89
874	The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. <b>2009</b> , 14, 253-63	591
873	Development of novel agents for bladder cancer. <b>2009</b> , 3, 160-169	
872	Caring for patients with malignancy in the emergency department: patient-provider interactions. <b>2009</b> , 27, 333-9	5
871	Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. <b>2009</b> , 27, 6229-36	77
870	Monitoring response to therapeutic interventions in patients with cancer. <b>2009</b> , 39, 210-32	31
869	Erlotinib for the treatment of non-small-cell lung cancer. <b>2009</b> , 10, 15-6	6
868	Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials. <b>2009</b> , 10, 885-94	51
867	Molecular predictive and prognostic markers in non-small-cell lung cancer. <b>2009</b> , 10, 1001-10	167
866	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. <b>2009</b> , 10, 1102-10	21
865	Arab A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803â27. <b>2009</b> , 15, 555-559	
864	Arab A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803â27. <b>2009</b> , 15, 560-566	
863	Gastrointestinal toxicities of novel agents in cancer therapy. <b>2009</b> , 45 Suppl 1, 332-42	23
862	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. <b>2009</b> , 373, 1525-31	1138
861	Maintenance therapy in non-small-cell lung cancer. <b>2009</b> , 374, 1398-400	15
860	Gefitinib in the treatment of advanced non-small-cell lung cancer. <b>2009</b> , 9, 401-12	17
859	Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase. <b>2009</b> , 7, 4415-27	36
858	EGFR signaling and drug discovery. <b>2009</b> , 77, 400-10	324

857	[Bevacizumab and non-small cell lung cancer: a new step?]. <b>2009</b> , 26, 125-38	1
856	[Long-term survivors of advanced non-small-cell lung cancer: characterisation and prognostic factors in a retrospective study]. <b>2009</b> , 26, 952-60	5
855	Aspects médico-économiques de la pneumologie. <b>2009</b> , 1, S195-S211	
854	Quel traitement en deuxième ligne métastatique des cancers bronchiques non ^petites cellules ?. <b>2009</b> , 1, 415-420	
853	Résistance acquise à l'érlotinib ; et si on continuait sur la même voie !. <b>2009</b> , 65, H9-H10	
852	Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. <b>2009</b> , 27, 4027-34	302
851	Stable disease is a valid end point in clinical trials. <b>2009</b> , 15, 374-8	13
850	Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. <b>2009</b> , 34, 346-9	19
849	Treatment of Advanced Lung Cancer. <b>2009</b> , 16, 157-171	2
848	Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy. <b>2009</b> , 32, 169-73	1
847	New targeted therapies for non-small-cell lung cancer. <b>2009</b> , 6, 335-350	4
846	Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. <b>2009</b> , 21, 445-54	35
845	Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. <b>2009</b> , 21, 116-23	10
844	A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. <b>2009</b> , 32, 269-73	30
843	Non-small-cell lung cancer: targeted therapies. <b>2009</b> , 6, 95-98	
842	Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. <b>2009</b> , 4, 311-7	49
841	Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. <b>2009</b> , 4, 684-8	59
840	Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy. <b>2009</b> , 4, 243-50	43

839	A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium. <b>2009</b> , 4, 1163-9	13
838	Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. <b>2009</b> , 4, 809-15	127
837	A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. <b>2009</b> , 4, 1002-9	56
836	Intracellular signaling molecules. <b>2009</b> , 4, S1057-8	1
835	Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. <b>2009</b> , 136, 1112-1118	36
834	Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. <b>2009</b> , 117, 209-28	25
833	Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. <b>2009</b> , 4, 1524-9	70
832	Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. <b>2009</b> , 4, 1136-43	23
831	Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. <b>2009</b> , 4, 994-1001	38
830	[EGFR and VEGF-targeted drugs: clinical evidence for their effects from evaluation of biomarkers]. <b>2009</b> , 133, 69-72	
829	Malignant Tumors of the Skin. <b>2009</b> , 1134-1155	
828	A Bayesian model for age, period, and cohort effects on mortality trends for lung cancer, in association with gender-specific incidence and case-fatality rates. <b>2009</b> , 4, 167-71	10
827	Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. <b>2009</b> , 4, 518-21	18
826	NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. <b>2009</b> , 7 Suppl 1, S5-21; quiz S22-4	87
825	Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. <b>2009</b> , 4, 862-8	38
824	Wood-smoke exposure as a response and survival predictor in erlotinib-treated nonsmall cell lung cancer patients. <b>2009</b> , 4, 1043	6
823	Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group. <b>2009</b> , 4, 1420-4	17
822	Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity. <b>2009</b> , 4, 1585-6	17

821	IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. <b>2009</b> , 4, 1126-35	43
820	MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib. <b>2009</b> , 4, 472-8	41
819	Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. <b>2009</b> , 4, 522-6	119
818	ERCC1 and RRM1 Expression in nonsmall cell lung cancer--the good, the bad and the unknown. <b>2009</b> , 4, 1042-3	5
817	Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. <b>2009</b> , 4, 1544-9	51
816	Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?. <b>2009</b> , 15, 354-60	13
815	Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. <b>2009</b> , 20, 856-66	43
814	Arab A, et al. Avaliao econmica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmo de no pequenas clulas Rev Port Pneumol 2008; 14(6):803-8271. <b>2009</b> , 15, 555-559	
813	Recent developments of targeted therapies in the treatment of non-small cell lung cancer. <b>2009</b> , 6, 91-102	24
812	Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. <b>2010</b> , 21, 151-68	9
811	Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives. <b>2010</b> , 5, 166-77	7
810	Personalized medicine in oncology: a personal view with myths and facts. <b>2010</b> , 5, 141-7	4
809	Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. <b>2010</b> , 11, 85-94	8
808	Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. <b>2010</b> , 5, 688-95	36
807	Evolving therapies and FAK inhibitors for the treatment of cancer. <b>2010</b> , 10, 722-34	34
806	Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients. <b>2010</b> , 5, 376-9	16
805	Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. <b>2010</b> , 5, 1105-6	30
804	Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. <b>2010</b> , 7, 121-124	2

803	Natural products derived from traditional chinese medicine as novel inhibitors of the epidermal growth factor receptor. <b>2010</b> , 13, 849-54	5
802	The role of pemetrexed in second-line chemotherapy for advanced non-small cell lung cancer. <b>2010</b> , 11, 58-60	4
801	Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. <b>2010</b> , 16, 1396-409	9
800	Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. <b>2010</b> , 11, 834-50	29
799	Gefitinib or Carboplatin+Paclitaxel in Pulmonary Adenocarcinoma. <b>2010</b> , 2010, 149-151	1
798	Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. <b>2010</b> , 11, 851-64	40
797	Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. <b>2010</b> , 5, 1048-53	68
796	Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. <b>2010</b> , 5, 1977-85	47
795	Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. <b>2010</b> , 5, 1197-200	62
794	Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401). <b>2010</b> , 5, 105-9	17
793	Molecular Diagnostics Testing for Lung Adenocarcinoma. <b>2010</b> , 15, 103-110	1
792	Is it prime time for personalized medicine in cancer treatment?. <b>2010</b> , 7, 387-397	1
791	Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis. <b>2010</b> , 16, 315-20	10
790	Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. <b>2010</b> , 21, 94-100	21
789	Uveal metastasis from nonsmall cell lung carcinoma with dramatic response to erlotinib. <b>2010</b> , 4, 390-3	10
788	Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. <b>2010</b> , 5, 1477-80	25
787	Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. <b>2010</b> , 5, 940-9	39
786	Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. <b>2010</b> , 5, 179-84	62

785	Non-small cell lung cancer. <b>2010</b> , 8, 740-801	457
784	Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. <b>2010</b> , 5, 1616-22	106
783	Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens. <b>2010</b> , 1, 147-150	6
782	Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. <b>2010</b> , 5, 950-5	103
781	Recent development of molecular-targeted drugs in lung cancer. <b>2010</b> , 49, 1923-34	6
780	Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. <b>2010</b> , 5, 1949-52	29
779	Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors. <b>2010</b> , 5, 82-9	17
778	Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer. <b>2010</b> , 5, 1726-33	8
777	Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. <b>2010</b> , 5, 491-6	35
776	Compassionate use programs or phase IV trials of innovative molecular targeted drugs in lung cancer: deal or no deal?. <b>2010</b> , 5, 1495-7	2
775	Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. <b>2010</b> , 5, 1855-8	32
774	A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer. <b>2010</b> , 5, 1068-74	7
773	Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. <b>2010</b> , 5, 1424-9	26
772	Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy. <b>2010</b> , 5, 540-5	27
771	The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. <b>2010</b> , 5, 1060-7	83
770	Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. <b>2010</b> , 5, 169-78	60
769	Cetuximab-induced skin exanthema: Improvement by a reactive skin therapy. <b>2010</b> , 3, 789-93	2
768	Maintenance chemotherapy in non-small cell lung cancer. <b>2010</b> , 8, 815-21	23



767	Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. <b>2010</b> , 5, 562-71	33
766	Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. <b>2010</b> , 5, 601-5	37
765	A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503. <b>2010</b> , 5, 1430-4	15
764	Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. <b>2010</b> , 5, 1609-15	29
763	Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer. <b>2010</b> , 5, 1662-3	16
762	Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. <b>2010</b> , 49, 103-7	26
761	Maintenance therapy in advanced non-small cell lung cancer. <b>2010</b> , 5, 723-34	15
760	A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. <b>2010</b> , 5, 99-104	61
759	Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time?. <b>2010</b> , 8, 822-32	31
758	Management of lung cancer in older adults. 110-123	
757	Endpoints in phase II trials for advanced non-small cell lung cancer. <b>2010</b> , 5, 3-9	32
756	Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients. <b>2010</b> , 5, 1042-7	9
755	RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. <b>2010</b> , 20, 1456-67	124
754	Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?. <b>2010</b> , 20, 2890-8	80
753	Systemische Therapie des nichtkleinzelligen Bronchialkarzinoms. <b>2010</b> , 3, 113-117	
752	Chronotherapy and the molecular clock: Clinical implications in oncology. <b>2010</b> , 62, 979-1001	118
751	Lung adenocarcinoma: lessons in translation from bench to bedside. <b>2010</b> , 77, 597-605	30
750	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. <b>2010</b> , 28, 4769-77	214

749	Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer. <b>2010</b> , 66, 913-8	12
748	[Molecular diagnostics in lung carcinoma for therapy stratification]. <b>2010</b> , 31, 22-8	3
747	[Molecular imaging in cancer therapy]. <b>2010</b> , 53, 810-7	
746	[Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects]. <b>2010</b> , 61, 654-61	9
745	ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent. <b>2010</b> , 34, 228-49	8
744	Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. <b>2010</b> , 878, 1059-68	73
743	Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array. <b>2010</b> , 26, 424-31	17
742	Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. <b>2010</b> , 136, 1937-44	25
741	Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer. <b>2010</b> , 15, 161-5	13
740	Efficacy of cetuximab combination with chemotherapy in non-small cell lung cancer first-line setting: the summary based on publications. <b>2010</b> , 9, 137-141	3
739	Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer: a report of 6 cases. <b>2010</b> , 9, 502-506	2
738	Fortgeschrittenes nichtkleinzelliges Bronchialkarzinom (NSCLC). <b>2010</b> , 7, 448-449	
737	Molekularpathologische Analyse beim metastasierten NSCLC. <b>2010</b> , 16, 63-66	1
736	[Implications of modern anticancer therapies for palliative care concepts]. <b>2010</b> , 24, 633-41	2
735	A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. <b>2010</b> , 18, 509-22	129
734	Head and neck cancer: a step forward. <b>2010</b> , 3, 85-89	
733	Impact of biomarkers on non-small cell lung cancer treatment. <b>2010</b> , 5, 5-17	14
732	Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. <b>2010</b> , 5, 65-72	43

731	EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. <b>2010</b> , 5, 245-55	50
730	Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial. <b>2010</b> , 5, 231-5	10
729	Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. <b>2010</b> , 27, 950-7	9
728	Biomarkers in bronchopulmonary cancer. <b>2010</b> , 12, 92-9	3
727	SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. <b>2010</b> , 12, 735-41	11
726	A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China. <b>2010</b> , 22, 1-9	1
725	âTargeted therapiesâIn der Behandlung solider Tumoren. <b>2010</b> , 3, 48-51	
724	EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. <b>2010</b> , 122, 685-97	60
723	Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. <b>2010</b> , 29, 37-48	75
722	Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. <b>2010</b> , 98, 93-9	155
721	Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. <b>2010</b> , 96, 219-30	172
720	Angiogenesis inhibitors: current strategies and future prospects. <b>2010</b> , 60, 222-43	350
719	A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer. <b>2010</b> , 11, 8-12	19
718	Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. <b>2010</b> , 11, 51-6	24
717	The emerging role of biomarkers in advanced non-small-cell lung cancer. <b>2010</b> , 11, 149-59	18
716	The 2010 Meeting of the American Society of Clinical Oncology. <b>2010</b> , 11, 303-310	1
715	Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. <b>2010</b> , 10, 26	20
714	Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. <b>2010</b> , 10, 376	48

713	Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature. <b>2010</b> , 10, 49	13
712	A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. <b>2010</b> , 10, 633	27
711	Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. <b>2010</b> , 80, 613-23	69
710	[Study of use of pemetrexed in non-small cell lung cancer]. <b>2010</b> , 34, 194-203	2
709	Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. <b>2010</b> , 119, 451-6	49
708	Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. <b>2010</b> , 14, 51-69	110
707	Activation of an oncogenic TBC1D7 (TBC1 domain family, member 7) protein in pulmonary carcinogenesis. <b>2010</b> , 49, 353-67	25
706	A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. <b>2010</b> , 116, 1526-34	142
705	Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer. <b>2010</b> , 116, 1336-43	80
704	Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. <b>2010</b> , 116, 3025-33	31
703	A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. <b>2010</b> , 116, 5686-93	34
702	Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines. <b>2010</b> , 18, 870-9	16
701	Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. <b>2010</b> , 18, 3812-22	44
700	Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer. <b>2010</b> , 78, 1020-5	21
699	Network meta-analysis: importance of appropriate trial selection. <b>2010</b> , 13, 681-2; author reply 683	4
698	The application of mass-spectrometry-based protein biomarker discovery to theragnostics. <b>2010</b> , 69, 367-78	14
697	Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression. <b>2010</b> , 101, 1424-30	33
696	Best supportive care in lung cancer trials is inadequately described: a systematic review. <b>2010</b> , 19, 293-301	12

695	Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. <b>2010</b> , 29, 2616-27	66
694	Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins. <b>2010</b> , 29, 4682-92	49
693	Targeting the cancer kinome through polypharmacology. <b>2010</b> , 10, 130-7	542
692	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. <b>2010</b> , 10, 241-53	410
691	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. <b>2010</b> , 10, 760-74	802
690	Integrating molecular diagnostics into anticancer drug discovery. <b>2010</b> , 9, 523-35	45
689	Personalized medicine in oncology: the future is now. <b>2010</b> , 9, 363-6	219
688	Identification of Biomarkers for Pharmacological Activity. <b>2013</b> , 189-205	1
687	Immunotherapy. <b>2017</b> , 227-237	1
686	Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. <b>2008</b> , 1307-1366	4
685	DEFINITIVE MANAGEMENT OF INOPERABLE NON-SMALL CELL LUNG CANCER. <b>2008</b> , 804-821	1
684	Biologics and Their Interactions with Radiation. <b>2012</b> , 83-94	1
683	Cancer of the Lung. <b>2014</b> , 1143-1192.e13	3
682	Developing an Improved Statistical Approach for Survival Estimation in Bone Metastases Management: The Bone Metastases Ensemble Trees for Survival (BMETS) Model. <b>2020</b> , 108, 554-563	9
681	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. <b>2012</b> , 58, 263-268	4
680	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. <b>2019</b> , 16, 341-355	192
679	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non-Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. <b>2006</b> , 1, 52-60	11
678	Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. <b>2006</b> , 1, 180-187	24

677	Salvage Therapy for Chinese Non-small Cell Lung Cancer Patients Who Failed Previous Chemotherapy. <b>2006</b> , 1, 545-550	6
676	Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer. <b>2006</b> , 1, 582-587	10
675	Immune-Modulating Vaccines in Non-small Cell Lung Cancer. <b>2006</b> , 1, 756-761	12
674	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. <b>2006</b> , 1, 965-971	33
673	A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. <b>2006</b> , 1, 1010-1019	16
672	Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?. <b>2008</b> , 3, 405-11	1
671	A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. <b>2010</b> , 5, 1806-14	43
670	The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. <b>2013</b> , 8, 171-8	66
669	Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors. <b>2005</b> , 70, 483-8	7
668	Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation. <b>2014</b> , 2014,	0
667	Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea. <b>2019</b> , 4,	14
666	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. <b>2017</b> , 2, e90449	30
665	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. <b>2006</b> , 116, 2695-706	372
664	Targeting TACE-dependent EGFR ligand shedding in breast cancer. <b>2007</b> , 117, 337-45	203
663	New molecularly targeted therapies for lung cancer. <b>2007</b> , 117, 2740-50	154
662	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. <b>2008</b> , 118, 2609-19	389
661	Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. <b>2012</b> , 122, 2637-51	65
660	Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. <b>2017</b> , 39, 1010428317705340	3

659	Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. <b>2013</b> , 20, 22-31	43
658	Metachronous rectal metastasis from pulmonary adenocarcinoma after 11 years of chemo-, immuno-, and radiotherapy for recurrent lesions: a case report. <b>2019</b> , 5, 151	2
657	Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. <b>2016</b> , 22, 276-83	12
656	Posterior Decompression Surgery and Radiofrequency Ablation Followed by Vertebroplasty in Spinal Metastases from Lung Cancer. <b>2020</b> , 26, e925169	3
655	Epidermal growth factor receptor inhibitor therapy for recurrent respiratory papillomatosis. <b>2013</b> , 2, 202	3
654	Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC). <b>2013</b> , 13, 202-17	5
653	Tobacco Smoking and Lung Cancer: Perception-changing facts. <b>2013</b> , 13, 345-58	54
652	Use of epidermal growth factor receptor mutation analysis in patients with advanced non-small-cell lung cancer to determine erlotinib use as first-line therapy. <b>2011</b> , 3, RRN1245	3
651	Incorporating molecular tools into early-stage clinical trials. <b>2008</b> , 5, e21	8
650	A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. <b>2010</b> , 5, e12417	42
649	Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells. <b>2011</b> , 6, e26073	35
648	Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma. <b>2012</b> , 7, e31884	13
647	Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib. <b>2013</b> , 8, e53081	30
646	Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data. <b>2013</b> , 8, e55637	30
645	Protein phosphorylation profiling using an in situ proximity ligation assay: phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cells. <b>2013</b> , 8, e55657	12
644	Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review. <b>2013</b> , 8, e59314	43
643	The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials. <b>2013</b> , 8, e62038	14
642	Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis. <b>2013</b> , 8, e67929	6

641	EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer. <b>2013</b> , 8, e72966	8
640	[ <sup>18</sup> F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients. <b>2014</b> , 9, e87629	22
639	Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study. <b>2014</b> , 9, e95897	20
638	Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer. <b>2014</b> , 9, e107276	19
637	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. <b>2015</b> , 10, e0142500	11
636	Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). <b>2016</b> , 11, e0147599	17
635	Inhibition of Ubiquitin-specific Peptidase 8 Suppresses Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells by Inducing Apoptosis. <b>2015</b> , 20, 57-63	16
634	Increasing output and low publication rate of Brazilian studies presented at the American Society of Clinical Oncology Annual Meetings. <b>2008</b> , 63, 293-6	7
633	Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/IV non-small cell lung cancer. <b>2008</b> , 8, 386-90	2
632	ALK-rearrangements and testing methods in non-small cell lung cancer: a review. <b>2014</b> , 5, 1-14	41
631	Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. <b>2013</b> , 4, 772-84	15
630	Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. <b>2016</b> , 7, 53299-53308	6
629	Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials. <b>2017</b> , 8, 7014-7024	8
628	Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies. <b>2016</b> , 7, 86902-86913	11
627	An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number. <b>2017</b> , 8, 17270-17278	2
626	Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. <b>2017</b> , 8, 29406-29415	7
625	Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. <b>2013</b> , 4, 2067-79	285
624	Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis. <b>2017</b> , 8, 33961-33971	10



623	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib chemotherapy in advanced non-small cell lung cancer patients. <b>2017</b> , 8, 57528-57536	7
622	Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro. <b>2017</b> , 8, 38568-38580	21
621	Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. <b>2017</b> , 8, 58709-58727	22
620	Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials. <b>2017</b> , 8, 73258-73270	3
619	A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. <b>2017</b> , 8, 69651-69662	20
618	Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer. <b>2017</b> , 8, 86816-86827	2
617	Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy. <b>2014</b> , 5, 3697-710	79
616	The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China. <b>2017</b> , 8, 87442-87454	6
615	Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. <b>2014</b> , 5, 10434-45	26
614	CONCORD biomarker prediction for novel drug introduction to different cancer types. <b>2018</b> , 9, 1091-1106	2
613	Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). <b>2018</b> , 9, 8253-8262	15
612	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. <b>2018</b> , 9, 14268-14284	9
611	Personalizing therapy with targeted agents in non-small cell lung cancer. <b>2011</b> , 2, 165-77	49
610	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. <b>2018</b> , 9, 18540-18547	9
609	The correlation of p22 and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma. <b>2019</b> , 10, 1119-1131	1
608	Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer. <b>2015</b> , 6, 13462-75	33
607	A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer. <b>2015</b> , 6, 22750-7	5
606	Putative effectors for prognosis in lung adenocarcinoma are ethnic and gender specific. <b>2015</b> , 6, 19483-99	4

605	Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. <b>2015</b> , 6, 30929-38	9
604	In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. <b>2015</b> , 6, 38789-803	104
603	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. <b>2015</b> , 6, 39538-49	23
602	Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. <b>2016</b> , 7, 21496-509	18
601	The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status. <b>2016</b> , 7, 35803-35812 <sup>6</sup>	6
600	Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. <b>2016</b> , 7, 40781-40791	6
599	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. <b>2016</b> , 7, 25632-9	6
598	IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. <b>2016</b> , 7, 42031-42044	38
597	Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. <b>2017</b> , 5, 371	2
596	Osimertinib in first-line treatment-is a comparison not proof?. <b>2018</b> , 6, 57	3
595	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. <b>2018</b> , 6, 143	6
594	VEGF inhibitors in -mutated lung cancer: a never-ending story?. <b>2018</b> , 6, 446	8
593	EGFR first- and second-generation TKIs-there is still place for them in -mutant NSCLC patients.. <b>2019</b> , 8, S23-S47	19
592	Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer.. <b>2019</b> , 8, 2425-2438	8
591	Impact of smoking on metabolic changes and effectiveness of drugs used for lung cancer. <b>2020</b> , 28, 53-58	4
590	Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. <b>2011</b> , 3, 21-34	2
589	Immunotherapy in first-line treatment of recurrent non-small cell lung cancer. <b>2019</b> , 132-136	1
588	Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. <b>2020</b> , 27, 5274-5316	9

587	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. <b>2019</b> , 19, 595-630	17
586	Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers. <b>2019</b> , 19, 2128-2142	5
585	From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. <b>2018</b> , 18, 1235-1240	5
584	The changing pattern of non-small cell lung cancer between the 90 and 2000 decades. <b>2011</b> , 5, 24-30	7
583	Results of Liquid Biopsy Studies by Next Generation Sequencing in Patients with Advanced Stage Non-small Cell Lung Cancer: Single Center Experience from Turkey. <b>2019</b> , 22, 17-24	4
582	An introduction to molecular targeted therapy of cancer. <b>2008</b> , 53, 130-8	15
581	Quantitative immunohistochemistry in lung cancer: clinical perspective. <b>2010</b> , 48, 7-11	5
580	Smoking cessation in lung cancer-achievable and effective. <b>2013</b> , 110, 719-24	14
579	Erlotinib for the treatment of relapsed non-small cell lung cancer. <b>2009</b> , 13, 41-47	4
578	Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. <b>2015</b> , 19, 1-134	8
577	The mutational landscape of hepatocellular carcinoma. <b>2015</b> , 21, 220-9	72
576	Efficacy and predictors of EGFR tyrosine kinase inhibitors in Chinese advanced lung adenocarcinoma: analyses of 253 cases from a single institute. <b>2014</b> , 21, 237-46	6
575	Consensus recommendations for optimizing biomarker testing to identify and treat advanced mutated non-small-cell lung cancer. <b>2020</b> , 27, 321-329	4
574	c-Met targeted therapy of cholangiocarcinoma. <b>2008</b> , 14, 2990-4	31
573	Exploiting novel molecular targets in gastrointestinal cancers. <b>2007</b> , 13, 5845-56	16
572	First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. <b>2013</b> , 19, 4511-9	12
57 <sup>1</sup>	[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer]. <b>2010</b> , 13, 171-89	6
57 <sup>0</sup>	[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified]. <b>2013</b> , 16, 138-43	6

569	[Role of HER2 in NSCLC]. <b>2015</b> , 18, 644-51	1
568	[China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)]. <b>2016</b> , 19, 1-15	8
567	Leveraging methylation to identify the potential causal genes associated with survival in lung adenocarcinoma and lung squamous cell carcinoma. <b>2020</b> , 20, 193-200	2
566	Effects of miR-218-1-3p and miR-149 on proliferation and apoptosis of non-small cell lung cancer cells. <b>2020</b> , 20, 96	2
565	Targeted Therapy for Non-Small Cell Lung Cancer. <b>2020</b> , 95, 78-88	1
564	The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. <b>2010</b> , 2, 144-53	7
563	Optimizing the use of epidermal growth factor receptor inhibitors in advanced non-small-lung cancer (NSCLC). <b>2011</b> , 3, 57-64	15
562	Treatment of advanced non small cell lung cancer. <b>2011</b> , 3, 122-33	69
561	High prevalence of gene abnormalities in young patients with lung cancer. <b>2013</b> , 5, 27-30	24
560	Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer. <b>2013</b> , 5, 400-5	13
559	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. <b>2013</b> , 5 Suppl 5, S579-92	29
558	Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. <b>2013</b> , 5, 585-92	21
557	Research status and funding trends of lung cancer biomarkers. <b>2013</b> , 5, 698-705	10
556	Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC. <b>2014</b> , 6, 356-68	1
555	Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. <b>2014</b> , 6, S502-25	9
554	Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status. <b>2014</b> , 6, 958-64	6
553	Pleural involvement in lung cancer. <b>2015</b> , 7, 1021-30	38
552	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <b>2015</b> , 7, E468-72	5

551	Vandetanib in advanced non small cell lung cancer: a promise unfulfilled. <b>2013</b> , 2, E7-9	1
550	Irreversible EGFR-TKIs: dreaming perfection. <b>2013</b> , 2, 40-9	19
549	EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data. <b>2013</b> , 2, 251-5	8
548	Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). <b>2013</b> , 2, 128-41	11
547	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. <b>2015</b> , 4, 36-54	389
546	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. <b>2014</b> , 3, 403-5	13
545	Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?. <b>2014</b> , 3, 395-6	12
544	Lung cancer biomarkers, targeted therapies and clinical assays. <b>2015</b> , 4, 503-14	19
543	Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. <b>2015</b> , 4, 465-74	16
542	Afatinib in the treatment of squamous non-small cell lung cancer: a new frontier or an old mistake?. <b>2016</b> , 5, 110-4	8
541	China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version). <b>2015</b> , 3, 260	6
540	[Lung cancer in smokers and never-smokers]. <b>2009</b> , 129, 1859-62	3
539	Comparison of Gefitinib and Erlotinib for Patients with Advanced Non-Small-Cell Lung Cancer. <b>2009</b> , 66, 280	2
538	From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer. <b>2011</b> , 2011, 312346	8
537	Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies. <b>2011</b> , 19, 371-389	6
536	Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers. <b>2016</b> , 143, 145-59	10
535	Image Findings of Rare Case of Peritoneal Carcinomatosis from Non Small Cell Lung Cancer and Response to Erlotinib in F-18 FDG Positron Emission Tomography/Computed Tomography. <b>2017</b> , 32, 140-142	3
534	The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India. <b>2013</b> , 19, 48-53	4

533	Integration of Early Specialist Palliative Care in Cancer Care and Patient Related Outcomes: A Critical Review of Evidence. <b>2016</b> , 22, 252-7	26
532	Targeted therapies in development for non-small cell lung cancer. <b>2013</b> , 12, 22	58
531	Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy. <b>2017</b> , 6, 1-5	2
530	Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. <b>2018</b> , 5, 430-434	2
529	Saudi lung cancer management guidelines 2017. <b>2017</b> , 12, 221-246	9
528	Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management. <b>2019</b> , 2, 36	2
527	Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line. <b>2017</b> , 54, 89-103	3
526	Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors. <b>2019</b> , 56, S23-S30	5
525	Erlotinib in Patients with Advanced Non-small Cell Lung Cancer in Middle Eastern Population. <b>2018</b> , 1, 19-25	0
524	Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update. <b>2019</b> , 8, 1-17	6
523	Association of single nucleotide polymorphisms in PIM-1 gene with the risk of Korean lung cancer. <b>2008</b> , 40, 190-6	8
522	Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment. <b>2011</b> , 43, 212-6	1
521	Present status and problems on molecular targeted therapy of cancer. <b>2012</b> , 44, 1-10	22
520	Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer. <b>2012</b> , 44, 74-84	9
519	Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. <b>2013</b> , 45, 79-85	18
518	Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial. <b>2015</b> , 47, 616-29	10
517	A Novel, Potent, Small Molecule AKT Inhibitor Exhibits Efficacy against Lung Cancer Cells In Vitro. <b>2015</b> , 47, 913-20	4
516	East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL). <b>2016</b> , 48, 1177-1186	13

515	Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. <b>2017</b> , 49, 1001-1011	29
514	Safety and Efficacy of Racotumomab-Alum Vaccine as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer. <b>2014</b> , 05, 844-850	2
513	Better Selection Model for EML4-ALK Fusion Gene Test in Patients with Non-Small-Cell Lung Cancer. <b>2013</b> , 04, 54-58	2
512	Current Algorithm for Treatment of Advanced NSCLC Patients: How to Include Active Immunotherapy?. <b>2013</b> , 04, 59-75	1
511	Current approach in the treatment of hepatocellular carcinoma. <b>2010</b> , 2, 348-59	69
510	Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures. <b>2006</b> , 4, 168-78	8
509	FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. <b>2014</b> , 6, 392-8	28
508	Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response. <b>2013</b> , 7, 611-5	12
507	Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer. <b>2015</b> , 11, 164-8	10
506	Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. <b>2011</b> , 2, 367-76	31
505	Review of the treatment of metastatic non small cell lung carcinoma: A practical approach. <b>2011</b> , 2, 262-71	7
504	Advances in adjuvant systemic therapy for non-small-cell lung cancer. <b>2014</b> , 5, 633-45	18
503	Positron emission tomography to assess hypoxia and perfusion in lung cancer. <b>2014</b> , 5, 824-44	8
502	Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature. <b>2014</b> , 5, 858-64	7
501	Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?. <b>2015</b> , 6, 45-56	3
500	Molecular Markers in Sex Differences in Cancer. <b>2019</b> , 35, 331-341	15
499	Non-small cell lung cancer--genetic predictors. <b>2013</b> , 157, 125-36	30
498	Studies Regarding Quality Enhancement of Affairs by Pharmacist and Clinical Evaluation of Cancer Chemotherapy. <b>2015</b> , 41, 289-310	1

497	Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. <b>2011</b> , 30, 327-35	28
496	Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. <b>2011</b> , 30, 5-12	86
495	The evolution of phase I trials in cancer medicine: a critical review of the last decade. <b>2011</b> , 30, 815-20	2
494	Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. <b>2011</b> , 135, 655-64	27
493	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. <b>2013</b> , 2, 265-282	41
492	Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. <b>2012</b> , 67, 419-24	34
491	EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. <b>2013</b> , 10, 320-30	85
490	Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer. <b>2012</b> , 13, 5119-24	3
489	Comparison of the efficacy and safety of EGFR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. <b>2012</b> , 13, 5177-82	39
488	Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients. <b>2013</b> , 14, 695-700	15
487	Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status. <b>2013</b> , 14, 3255-61	9
486	Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model. <b>2014</b> , 15, 69-73	4
485	A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer. <b>2015</b> , 16, 4797-800	4
484	Lung cancer in women, a different disease: survival differences by sex in Turkey. <b>2015</b> , 16, 815-22	13
483	Types of Cancers Prevailing in Pakistan and their Management Evaluation. <b>2015</b> , 16, 3605-16	3
482	Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China. <b>2016</b> , 17, 965-71	19
481	Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI. <b>2014</b> , 11, 270-6	12
480	FGL2 is positively correlated with enhanced antitumor responses mediated by T cells in lung adenocarcinoma. <b>2020</b> , 8, e8654	5



- 479 Algorithmhe thérapeutique des CBNPC sans anomalie moléculaire actionnable. **2021**, 13, 2S121-2S134
- 478 Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation. **2021**, 9, 0
- 477 Contextualizing Genes by Using Text-Mined Co-Occurrence Features for Cancer Gene Panel Discovery. **2021**, 12, 771435 1
- 476 Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas. **2021**, 13, 1
- 475 Radioresistance of Human Cancers: Clinical Implications of Genetic Expression Signatures. **2021**, 11, 761901 1
- 474 Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors. **2021**, 21, 1089 1
- 473 Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment. **2021**, 31, 399-406 0
- 472 EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC. **2021**, 16, 1793-1797 0
- 471 Regulatory Points to Consider on Multiplicity Issues in Clinical Trials of New Drug Applications. **2006**, 27, S78-S87
- 470 5. ??????. **2007**, 38, 393-400
- 469 Malignome des Respirationstrakts. **2007**, 511-548
- 468 Erlotinib in Previously Treated Non-Small-Cell Lung Cancer. **2007**, 2007, 144-146 0
- 467 Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. **2007**, 2007, 210-211
- 466 Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman. **2007**, 39, 37-9 2
- 465 Epidermal Growth Factor Receptor Inhibition in Non-Small Cell Lung Cancer. **2007**, 81-96
- 464 Epidermal Growth Factor Receptor Targeted Therapy—Markers of Sensitivity and Response. **2007**, 97-122
- 463 Other Novel Targeted Therapies in Lung Cancer. **2007**, 123-148
- 462 Early Clinical Trial Design Issues: Patient Populations, End Points, and Barriers. **2007**, 25-44

- 461 Safety of targeted therapies. **2007**, 141-155
- 460 Combination treatment. **2007**, 135-140
- 459 TRAIL Modulators. **2007**, 219-234
- 458 Erlotinib (Tarceva<sup>®</sup>) in Second/Third Line Treatment for Non-Small Cell Lung Cancer (NSCLC) – Case Description. **2007**, 1, 307-313
- 457 Signal Transduction Inhibitors, HER Family, EGFR Inhibition and Clinical Achievements. **2007**, 19-44
- 456 Traitement des cancers bronchique, colorectal, du sein et de l’ovaire. **2008**, 621-644
- 455 Selecting the Right Targets for Cancer Therapy. **2008**, 1-26
- 454 II ??????????. **2008**, 119, 285-292
- 453 BIOLOGY AND EPIDEMIOLOGY OF LUNG CANCER. **2008**, 708-728 o
- 452 Cellular sensitivity to EGF receptor inhibitors. **2008**, 340-355
- 451 HER Family of Receptors as Treatment Targets in Pancreatic Cancer. **2008**, 609-634
- 450 Cell Adhesion Molecules. **2008**, 22-39
- 449 Response to Conventional Therapy and Targeted Molecular Therapy. **2008**, 226-232
- 448 Molecular Pathology of Squamous Cell Carcinoma and Its Precursors. **2008**, 270-278
- 447 Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. **2008**, 317-365
- 446 The intersection of EGFR and the Ras signaling pathway. **2008**, 84-90
- 445 EGFR family heterodimers in cancer pathogenesis and treatment. **2008**, 14-29 3
- 444 Pitfalls in Clinical Trials and Future Directions. **2008**, 723-731

- 443 The EGF(R) and VEGF(R) Pathways as Combined Targets for Anti-Angiogenesis Trials in Cancer Therapy. **2008**, 707-715 o
- 442 EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer. **2008**, 281-324
- 441 Prognostic Markers. **2008**, 193-199
- 440 Targeted Therapy of Lung Cancer. **2008**, 51, 483
- 439 Systemic Therapy. **2008**, 449-483
- 438 [Tumor vasculature as a therapeutic target in non-small cell lung cancer]. **2008**, 52, 247-59 3
- 437 Targeting Signaling Pathways in Cancer Therapy. **2009**, 309-326
- 436 LUNG CANCER. **2009**, 921-931
- 435 Principles of Modern Chemotherapy and Endocrine Therapy. **2009**, 1345-1352
- 434 Targeted Approaches to Drug Development. **2009**, 57-98 o
- 433 Combined Targeting of EGFR and Angiogenesis in Aerodigestive Carcinomas. **2009**, 297-307
- 432 Immuntherapeutika und Zytostatika. **2009**, 621-635
- 431 The Impact of Molecularly Targeted Therapy in Multi-Modality Therapy. **2009**, 191-219
- 430 Terminating Chemotherapy and Transition to Palliative Care for Patients with Recurrent Non-small Cell Lung Cancer in the Terminal Stage. **2009**, 49, 836-843
- 429 Advances in the Treatment of Lung Cancer. **2009**, 545-552
- 428 Selective Use of Gefitinib and Erlotinib on Non-small Cell Lung Cancer Patients. **2009**, 49, 950-956
- 427 Lungen- und Atemwegserkrankungen. **2009**, 275-376
- 426 Contributions of Targeted Agents. **2009**, 215-223

- 425 Individualization of treatment in non-small cell lung cancer. **2009**, 1, 1
- 424 Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. **2009**, 2, 251-60 1
- 423 Classification of Anticancer Drugs Based on Therapeutic Targets. **2010**, 3-35 1
- 422 Principles of Systemic Therapy. **2009**, 27-40
- 421 Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. **2009**, 3, 9-18
- 420 Angiogenesis Inhibitors in Lung Cancer. **2010**, 227-252 1
- 419 Clinical Aspects of Lung Cancer. **2010**, 1116-1144 1
- 418 Pharmacogenetics in Lung Cancer. **2010**, 87-99
- 417 Chemotherapy in Previously Treated Patients with Non-small Cell Lung Cancer. **2010**, 195-204
- 416 Vaccine Therapy for Lung Cancer. **2010**, 279-303 1
- 415 Biologisch zielgerichtete medikamentöse Therapie. **2010**, 265-275
- 414 Targeting EGFR in HPV-Associated Cancer. **2010**, 211-234
- 413 DRUGS USED IN CANCER CHEMOTHERAPY. **2010**, 1-229
- 412 Pulmonary Toxicity of Therapy. **2010**, 99-105
- 411 Nonobstructive Lung Disease and Thoracic Tumors. **2010**, 376-384
- 410 Overview of Efficacy and Limitation of Standard and Targeted Therapy for Malignant Disease Using Lung Cancer as a Case Study. **2010**, 3-21
- 409 Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer. **2010**, 205-226 0
- 408 Molecular Targeted Therapy. **2010**, 1523-1531

- 407 Tumor Microenvironment. **2010**, 27-69 1
- 406 Tumors of the Lung, Pleura, and Mediastinum. **2010**, 737-771 1
- 405 Other Molecular Targeted Agents in Non-small Cell Lung Cancer. **2010**, 253-278
- 404 Quality of Life for Patients Receiving Cancer Chemotherapy: The Japanese Perspective. **2010**, 2923-2933
- 403 Immuntherapeutika und Zytostatika. **2010**, 649-664
- 402 Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. **2010**, 33, 148-52 7
- 401 Epidermal Growth Factor Receptor-Targeted Therapies. **2011**, 305-333
- 400 Unresectable Pancreatic Cancer. **2011**, 205-224
- 399 Protein Kinase Inhibitors. **2011**, 319-330
- 398 Thérapies ciblées. **2011**, 127-133
- 397 Facteurs prédictifs pour un traitement personnalisé des cancers bronchiques non à petites cellules. **2011**, 103-125
- 396 Traitements de rattrapage du cancer bronchique non à petites cellules. **2011**, 135-146
- 395 Resistance to Targeted Therapies As a Result of Mutation(s) in the Target. **2011**, 1-31
- 394 Encyclopedia of Cancer. **2011**, 2111-2115
- 393 Pharmacogenomics and Personalized Medicine. **2011**, 1359-1382
- 392 Lung Cancer in Older Patients. **2012**, 89-109
- 391 Use of rHuG-CSF in New Chemotherapy Strategies. **2012**, 225-247
- 390 Erlotinib for advanced non-small cell lung cancer.

389 EGF receptor-targeted drugs. **2011**, 18-37

388 Targeting Signal Transducer and Activator of Transcription (STAT) for Anticancer Therapy. **2012**, 299-321

387 Facharzt Hämatologie Onkologie - Pages e1-e61. **2012**, e1-e61

386 The Respiratory System. **2012**, 321-394

385 Targeted Therapies for Non-small-Cell Lung Cancer. **2012**, 93-114

384 Salivary Gland Malignancies. **2012**, 691-706

383 Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases. **2012**, 2, 1-9

5

382 Treatment of non-small cell lung cancer in the era of targeted therapy. **2012**, 01, 1-4

381 Molecular Targeted Therapy of Lung Cancer. **2012**, 99-107

380 A Case of EGFR-wild-type Adenocarcinoma of Recurrent Non-small Cell Lung Cancer Responding to Erlotinib. **2012**, 52, 315-319

0

379 A surgical intervention followed by adjuvant treatment of erlotinib for a 85-year-old elderly advanced lung cancer. **2012**, 20, 01-06

378 Clinical Analysis of 17 Cases Beginning Treatment with Erlotinib the Day After Terminating Gefitinib for Advanced Non-small Cell Lung Cancer. **2012**, 52, 871-877

377 A new targeted treatment for lung cancer patients. **2012**, 3, 103-6

376 Second-line therapy of non-small cell lung cancer. **2012**, 85-92

375 Predictive Markers in Lung Cancer. **2013**, 43-68

374 VEGF inhibitors. **2012**, 34-45

373 Lung Cancer. **2013**, 119-138

372 FDG-PET for predicting efficacy of EGFR-tyrosine kinase inhibitors in lung cancer. **2013**, 3, 104

371 Prerequisite Genetic Traits for Metastasis. **2013**, 403-444

370 Six Cases of Lung Adenocarcinoma Successfully Treated Using Alternate Day Administration of Gefitinib. **2013**, 53, 25-28

369 EGFR, Immunology. **2013**, 1-10

368 Reanalysis of the EGFR Mutation Status in Non-small Cell Lung Cancer Patients Without an EGFR Mutation Treated with Erlotinib. **2013**, 53, 324-328

367 Behavior of circulating epithelial tumor cells (CETC) and FISH (fluorescence &lt;i>in situ</i>) hybridisation) of epidermal growth factor receptor (EGFR)-gene amplification in lung cancer patients during the course of therapy. **2013**, 02, 1-8

366 Kombination von Zytostatika mit Strahlentherapie: Radiochemotherapie. **2013**, 249-269

365 Psychoonkologie in der Pneumologie. **2013**, 365-378

364 Are Second- and Third-Line Treatments in the Elderly Feasible?. **2013**, 213-220

363 TYPES OF DNA DAMAGE. **2013**, 115-118

362 Retrospective Survey of the Efficacy of Erlotinib for Non-small Cell Lung Cancer Patients Previously Treated with Gefitinib. **2013**, 39, 104-109 1

361 The Efficacy and Cost of Biological Targeted Agents in Oncology.

360 Systemic Therapy for Lung Cancer. **2013**, 125-135

359 Influence of smoking on medication efficacy. **2013**, 276-292

358 Chemotherapy and molecularly targeted agents for advanced non-small-cell lung cancer. **2013**, 102-113

357 Epidermal Growth Factor Receptor Testing in Lung Adenocarcinoma. **2014**, 15-22

356 Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. **2014**, 75-118

355 Signal Transduction Inhibitors of the HER Family. **2013**, 17-50

354 Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer. **2013**, 32, 539-45 1

- 353 Epidermal Growth Factor Receptor Inhibitor Reactions. 184-195
- 352 The Role of Phase III Trials in Modern Drug Development. **2014**, 763-783
- 351 Longcarcinoom. **2014**, 117-124
- 350 Crizotinib in non-small cell lung cancer. **2014**, 03, 5-9
- 349 A Phase II Study of Erlotinib in Patients with Previously Treated Non-Small Cell Lung Cancer. **2014**, 03, 10-20
- 348 Introduction. **2014**, 1-6
- 347 EGFR-Targeted Therapies in Non-small Cell Lung Cancer. **2014**, 31-66
- 346 Portfolio Optimization of Therapies and Their Predictive Biomarkers. **2015**, 155-180 ○
- 345 Perspectives on Nintedanib Treatment in Non-small Cell Lung Cancer. **2015**, 55, 962-972
- 344 Pharmacogenetics and Antineoplastic Therapies. **2015**, 275-305
- 343 Encyclopedia of Cancer. **2015**, 1-5
- 342 Encyclopedia of Cancer. **2015**, 1553-1559
- 341 Lung Cancer: Diagnosis and Treatment Approach. **2015**, 97-144 2
- 340 Onkologika. **2015**, 833-876
- 339 E28 Literaturhinweise und Internetadressen. **2015**, e1-e79
- 338 Revisi3n del tratamiento y sobrevida del mesotelioma pleural maligno en el INER. **2015**, 74, 184-189
- 337 Encyclopedia of Cancer. **2015**, 1-7
- 336 The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer. **2015**, 47, 638-44



- 335 Non-small cell lung cancer and superior vena cava obstruction. **2015**, 11-24
- 334 Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer. **2015**, 16, 5521-4 5
- 333 A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer. **2015**, 16, 5963-6 3
- 332 Erlotinib. **2016**, 97-98 1
- 331 Molecular Targeted Anticancer Drugs. **2016**, 175-238
- 330 ??????????EGFR-TKI?????. **2016**, 56, 985-987
- 329 Disparities in Lung Cancer Outcomes. **2016**, 237-264 1
- 328 Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors. **2016**, 121-150
- 327 Current status and prospects of targeted therapies non-small cell lung cancer. **2016**, 10, 15-18
- 326 Have adjuvant tyrosine kinase inhibitors lost their shine?. **2016**, 4, 285 0
- 325 Oncogenes and the Initiation and Maintenance of Tumorigenesis. **2017**, 143-157
- 324 Biological Principles and Clinical Application of EGFR Inhibitors in Cancer. **2017**, 709-726
- 323 Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation. **2016**, 16, 280-285 1
- 322 An Overview. **2017**, 1-7
- 321 Encyclopedia of Cancer. **2017**, 2591-2595
- 320 Cancer Drug Delivery. **2017**, 185-228
- 319 The Role of Angiogenesis in Non-small Cell Lung Cancer Tumor Behavior. **2017**, 217-239
- 318 Companion Diagnostics. **2017**, 117-136

- 317 Patient-Derived Xenografts From Lung Cancer and Their Potential Applications. **2017**, 273-289
- 316 EGFR Mutant. **2017**, 167-189
- 315 Targeted Therapies for Lung Cancer. **2018**, 239-255
- 314 Developing a Translational Toxicology Therapeutic Portfolio for Cancer Risk Reduction. 691-710
- 313 Receptor Tyrosine Kinases in Human Platelets: A Review of Expression, Function and Inhibition in Relation to the Risk of Bleeding or Thrombocytopenia from Phase I through Phase III Trials. **2017**, 8, 0
- 312 Lung Cancer. **2018**, 85-103
- 311 Literaturverzeichnis. **2018**, 503-517
- 310 Superiority and Non-inferiority Phase III Oncology Trials. **2018**, 203-216
- 309 Lung Cancer in Older Adults: Systemic Treatment. **2018**, 1-13
- 308 Diarrhea, Constipation, and Obstruction in Cancer Management. **2018**, 421-436 1
- 307 Management of Lung cancer. **2018**, 23-33
- 306 Onkologika. **2018**, 645-691 1
- 305 Hepatotoxicity and Hepatic Dysfunction. **2018**, 445-465
- 304 Regulation of the error-prone DNA polymerase  $\delta$  by oncogenic signaling and its contribution to drug resistance.
- 303 Treatment of patients with non-small cell cancer and EGFR mutations. **2018**, 12, 175-181
- 302 Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions. 001-005
- 301 Non-small Cell Lung Cancer. **2019**, 143-192
- 300 Unmet Needs and Future Outlook of Mesothelioma Management. **2019**, 331-340

- 299 Onkologika. **2019**, 817-875
- 298 Acneiform rash âskin toxic reaction to the use of EGFR inhibitors. **2019**, 8, 48-55 1
- 297 Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation. **2019**, 64-71 1
- 296 Carcinoembryonic antigen in pleural effusion of patients with lung adenocarcinoma: a predictive marker for EGFR mutation.. **2019**, 8, 1027-1034
- 295 Le sevrage tabagique dans le cancer bronchique: les mthodes et les rultats; place de la e-cigarette. **2019**, 11, 177-183
- 294 Les CBNPC de stades avanc hors addiction oncoghique: les traitements systmiques de deuxime ligne. **2019**, 11, 355-363
- 293 Antiangiogenic therapy of advanced non-squamous non-small cell lung cancer in era of immuno-oncology: role, place and optimization of treatment approaches. **2019**, 3, 18-24
- 292 Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer. **2020**, 9, 47-49
- 291 Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer. **2020**, 1, 117-130
- 290 Role of Erlotinib in Influencing the Quality of Life of Cancer Patients. **2020**, 07,
- 289 Adverse reactions during chemotherapy: skin toxicity. **2020**, 28-64
- 288 Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. **2021**, 13, 4
- 287 Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. **2021**, 11, 4
- 286 EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1. **2021**, 4, 1237 5
- 285 Cardiovascular Toxicities of Targeted Therapy. **2020**, 165-178
- 284 Chapter 17: Oncology: Somatic Disease and Pharmacogenomics. **2020**,
- 283 Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer. **2019**, 10, 6297-6307
- 282 Lung cancer. **2020**, 4338-4359

- 281 Lung Cancer in Older Adults: Systemic Treatment. **2020**, 799-811
- 280 Development of Pharmacodynamic Biomarkers for Phase I Trials. **2020**, 139-158
- 279 Targeting lung cancer using advanced drug delivery systems. **2020**, 493-516 1
- 278 Cancer Drug Delivery. 52-95
- 277 North American Cooperative Group Research Efforts in Lung Cancer. **2006**, 451-461
- 276 Applications in Lung Cancer. **2006**, 231-250
- 275 Advanced Non-Small Cell Lung Cancer: Second-Line Treatment with Docetaxel. **2008**, 269-280
- 274 Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib. **2008**, 291-306
- 273 Tobacco control. 24-37
- 272 Achievements in targeted therapies. 215-233
- 271 Tyrosine Kinase Inhibitors. **2007**, 477-508
- 270 Untargeted Use of Targeted Therapy. **2008**, 227-240
- 269 Clinical Trial Design with Targeted Agents. **2008**, 649-655
- 268 Targeted Therapy in Non-Small Cell Lung Cancer. **2008**, 125-156
- 267 Rehabilitation and palliation of patients with bronchial cancer. **2007**, 335-384
- 266 Neue Arzneimittel. **2007**, 47-104
- 265 Chemotherapy in the Management of Malignant Tumors of Salivary Gland Origin. **2007**, 477-494
- 264 Tyrosine kinase inhibitors in the treatment of advanced lung cancer from example of preferential medicine provision in Moscow city. **2020**, 30, 463-472 1

263	Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists. <b>2020</b> , 16, 5-10	
262	Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutations.	1
261	Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study. <b>2021</b> , 80, 100795	0
260	A time to test, a time to treat. <b>2012</b> , 4, 223-5	1
259	[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer]. <b>2014</b> , 17, 391-400	1
258	First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?. <b>2012</b> , 1, 219-23	4
257	EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy?. <b>2012</b> , 1, 269-75	5
256	Renal cell carcinoma and the use of sorafenib. <b>2006</b> , 2, 87-98	11
255	Biological response modifiers in cancer. <b>2006</b> , 8, 33	4
254	Review of erlotinib in the treatment of advanced non-small cell lung cancer. <b>2007</b> , 1, 335-46	22
253	Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. <b>2007</b> , 1, 185-94	4
252	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. <b>2009</b> , 3, 215-24	24
251	Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. <b>2009</b> , 1, 101-14	11
250	Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. <b>2009</b> , 34, 554-64	15
249	Lung cancer. <b>2009</b> , 2009,	1
248	A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. <b>2009</b> , 15, 213-20	8
247	Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer. <b>2011</b> , 36, 263-79	14
246	Lung cancer. <b>2010</b> , 2010,	

245	The role of gene expression profiling in early-stage non-small cell lung cancer. <b>2010</b> , 2, 89-99	27
244	Patient selection in non-small cell lung cancer: Histologic versus molecular subtypes?. <b>2010</b> , 2, 189-91	1
243	Transcription Factor DLX5 As a New Target for Promising Antitumor Agents. <b>2011</b> , 3, 47-51	2
242	Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. <b>2010</b> , 10, 1-48	23
241	Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. <b>2013</b> , 25, 90-4	12
240	EATRIS, a European initiative to boost translational biomedical research. <b>2013</b> , 3, 166-74	7
239	Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer. <b>2013</b> , 25, 200-5	7
238	Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer. <b>2012</b> , 9, 38-43	
237	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. <b>2013</b> , 5, 481-96	13
236	EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence. <b>2013</b> , 6, 2800-12	25
235	Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. <b>2006</b> , 12, 5160-7	18
234	Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. <b>2014</b> , 17, 101-14	35
233	Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition). <b>2014</b> , 6, 1489-98	2
232	Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. <b>2015</b> , 3, 32	
231	Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?. <b>2015</b> , 3, 31	1
230	A new proteomic test could guide treatment decision in second-line therapy for patients with EGFR unselected non-small cell lung cancer?. <b>2015</b> , 3, 30	
229	MET inhibitors in combination with other therapies in non-small cell lung cancer. <b>2012</b> , 1, 238-53	19
228	The TORCH trial. <b>2012</b> , 1, 283-6	1

227	Expanding options for EGFR targeting in lung cancer. <b>2012</b> , 1, 287-8	2
226	Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. <b>2012</b> , 1, 227-9	
225	Is there a third line option after chemotherapy and TKI failure in advanced non-small cell lung cancer?. <b>2012</b> , 1, 152-4	1
224	Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis. <b>2012</b> , 1, 129-44	2
223	Advances on EGFR mutation for lung cancer. <b>2012</b> , 1, 5-13	38
222	Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy. <b>2012</b> , 1, 72-7	3
221	Personalized maintenance therapy in advanced non-small cell lung cancer. <b>2013</b> , 2, 452-6	
220	Influence of chemotherapy on EGFR mutation status. <b>2013</b> , 2, 442-4	7
219	Does the order of factors affect the product? Lessons learned from the TORCH trial. <b>2013</b> , 2, 50-4	
218	Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL study. <b>2013</b> , 2, 58-61	1
217	Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice. <b>2014</b> , 3, 173-80	13
216	Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. <b>2013</b> , 2, 411-4	1
215	Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river's DELTA?. <b>2015</b> , 7, 227-9	
214	Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?-An update incorporating the DELTA trial data. <b>2015</b> , 7, 224-6	1
213	Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer. <b>2015</b> , 8, 10330-9	16
212	A multi-center phase II study of nintedanib as second-line therapy for patients with advanced non-small-cell lung cancer in China. <b>2015</b> , 5, 3270-5	2
211	Curative effect analysis of different treatments for gefitinib-resistance advanced non-small cell lung cancer patients. <b>2015</b> , 8, 16064-70	2
210	Primary ovarian cancer cell inhibition by human Wharton's Jelly stem cells (hWJSCs): Mapping probable mechanisms and targets using systems oncology. <b>2015</b> , 11, 529-34	2

209	Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma. <b>2016</b> , 4, 50	8
208	A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer. <b>2016</b> , 28, 12-8	1
207	Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience. <b>2016</b> , 13, 136-41	1
206	Effects of targeted silencing of FOXC1 gene on proliferation and in vitro migration of human non-small-cell lung carcinoma cells. <b>2016</b> , 8, 3309-18	16
205	Role of epidermal growth factor receptor in lung cancer and targeted therapies. <b>2017</b> , 7, 187-202	39
204	Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer. <b>2016</b> , 36, 1759-65	2
203	Assessment of very early response evaluation with F-FDG-PET/CT predicts survival in erlotinib treated NSCLC patients-A comparison of methods. <b>2018</b> , 8, 50-61	4
202	[Clinical Observation of Gefitinib with Pericardial Perfusion for ?Advanced Non-small Cell Lung Cancer]. <b>2018</b> , 21, 37-42	
201	[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment?(2016 version)]. <b>2016</b> , 19, 489-94	6
200	[Efficacy of Cetuximab in Combination with Chemotherapy in Advanced Non-small Cell Lung Cancer]. <b>2016</b> , 19, 263-8	
199	[Treatment of Advanced Squamous Cell Lung Cancer]. <b>2016</b> , 19, 687-691	3
198	Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC). <b>2018</b> , 8, 879-891	7
197	[Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy]. <b>2011</b> , 14, 699-703	
196	[Pemetrexed alone versus pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma]. <b>2011</b> , 14, 704-9	
195	[Analysis of prognostic factors in 541 female patients with advanced non-small cell lung cancer]. <b>2011</b> , 14, 245-50	2
194	[Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer]. <b>2011</b> , 14, 261-5	2
193	[Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma]. <b>2011</b> , 14, 127-31	3
192	[Clinical Analysis of Icotinib on Beneficiary of ?Advanced Non-small Cell Lung Cancer with EGFR Common Mutation]. <b>2016</b> , 19, 200-6	3



- 191 [Gemcitabine combined with vinorelbine in the treatment of refractory patients with advanced non-small cell lung cancer: a multi-center retrospective study]. **2012**, 15, 507-12
- 190 [Efficacy of pemetrexed as second-line therapy or beyond in patients with advanced non-small cell lung cancer]. **2012**, 15, 179-82 1
- 189 [Vandetanib for advanced non-small cell lung cancer: a meta-analysis]. **2012**, 15, 172-8 1
- 188 [Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy]. **2011**, 14, 529-33
- 187 [Progress in Tissue Specimens Alternative for the Driver Genes Testing of Non-small Cell Lung Cancer]. **2015**, 18, 387-90
- 186 [Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib]. **2011**, 14, 785-9 0
- 185 [Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis]. **2012**, 15, 44-8 1
- 184 [Current status and future direction of multi-targeted drugs in the era of personalized therapy--overview of advances in multi-targeted therapy in non-small cell lung cancer]. **2011**, 14, 874-9
- 183 [Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status]. **2014**, 17, 321-6 1
- 182 [Research Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Benefit from EGFR-TKI]. **2015**, 18, 518-22
- 181 [China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)]. **2015**, 18, 397-400 1
- 180 [Clinical investigation of efficacy of third-line and beyond pemetrexed treatment in advanced non-squamous non-small cell lung cancer]. **2012**, 15, 117-21 1
- 179 [Analysis of the efficacy and survival of third-line treatment in advanced non-small cell lung cancer]. **2012**, 15, 369-74
- 178 [Fourth-line and beyond therapy in advanced non-small cell lung cancer: a retrospective analysis]. **2014**, 17, 839-44
- 177 [Efficacy of gefitinib for young patients with unknown EGFR gene mutation ?in advanced lung adenocarcinoma]. **2014**, 17, 401-5
- 176 [Prospective study on surface-enhanced laser desorption/ionization protein fingerprinting for diagnosing gene polymorphism leading to drug resistance drift: sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung cancer]. **2013**, 16, 33-7
- 175 [Analysis of prognostic factors in patients with stage IV lung adenocarcinoma after failure of second-line EGFR-TKIs therapy]. **2013**, 16, 38-42
- 174 [Treatment progress for EGFR wild-type advanced non-small cell lung cancer]. **2014**, 17, 575-80

173	[Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months]. <b>2010</b> , 13, 1050-5	1
172	[Relationship between BIM gene polymorphism and therapeutic efficacy in the retreatment of advanced non-small cell lung cancer with tyrosine kinase inhibitor]. <b>2013</b> , 16, 632-8	4
171	[Value of surgery for stage IIIa non-small cell lung cancer]. <b>2013</b> , 16, 639-45	
170	[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?]. <b>2013</b> , 16, 345-52	3
169	[Application of epidermal growth factor receptor tyrosine kinase inhibitor as the first-line therapy in patients with advanced non-small cell lung cancer]. <b>2010</b> , 13, 48-53	3
168	[A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer]. <b>2010</b> , 13, 363-9	
167	Long-Term Survival of a Patient With Late-Stage Non-Small Cell Lung Cancer. <b>2016</b> , 33, 635-655	
166	Effect of EGFR gene polymorphism on efficacy of chemotherapy combined with targeted therapy for non-small cell lung cancer in Chinese patients. <b>2019</b> , 9, 619-627	6
165	[Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them]. <b>2019</b> , 22, 299-305	
164	Identification of EGFR mutations in cytological specimens of non-small cell lung carcinoma from a single institute. <b>2018</b> , 11, 929-935	1
163	Immunotherapy in non-small cell lung cancer: Update and new insights. <b>2021</b> , 7, 1-21	4
162	Recent advances in lung cancer genomics: Application in targeted therapy. <b>2021</b> , 108, 201-275	0
161	Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?. <b>2021</b> , 169, 103538	2
160	Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. <b>2021</b> , 1877, 188645	4
159	Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients. <b>2021</b> , 21, 1225	
158	Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase the WHO Global Database of Individual Case Safety Reports. <b>2021</b> , 13,	0
157	Identification of Patients with Recurrent Epithelial Ovarian Cancer Who Will Benefit from More Than Three Lines of Chemotherapy. <b>2021</b> ,	0
156	Feasibility and safety of shortened hypofractionated high dose palliative lung radiotherapy â A retrospective planning study.	

155	Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world. <b>2021</b> , 11, 86	6
154	Immune-Related Oral, Otologic, and Ocular Adverse Events.. <b>2021</b> , 1342, 399-416	0
153	Les biomarqueurs g�nomiques: contribution des tests diagnostiques  la mdecine personnalise. <b>2008</b> , 27, 8-15	
152	NNMT Promotes Aerobic Glycolysis and Tumorigenesis by Upregulating EGFR Expression in Cholangiocarcinoma.	
151	Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.. <b>2022</b> , 27, e286-e293	0
150	Drug-Specific Orofacial Complications of Novel Anti-cancer Therapies. <b>2022</b> , 153-169	
149	Oral Mucositis. <b>2022</b> , 49-97	1
148	In3+ doped magnesium ferrite an efficient magnetic catalyst for the synthesis of functionalized quinazolinone and Henry reaction. <b>2022</b> , 134, 1	0
147	Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.. <b>2022</b> , 120, 105605	1
146	Clinical and CT patterns to predict EGFR mutation in patients with non-small cell lung cancer: A systematic literature review and meta-analysis.. <b>2022</b> , 9, 100400	1
145	Deciphering the Mechanism of Binding Selectivity of Chlorofluoroacetamide-Based Covalent Inhibitors toward L858R/T790M Resistance Mutation.. <b>2022</b> ,	1
144	Current Therapy and Development of Therapeutic Agents for Lung Cancer. <b>2022</b> , 100015	1
143	Emerging Molecular Dependencies of Mutant EGFR-Driven Non-Small Cell Lung Cancer.. <b>2021</b> , 10,	0
142	Anticancer drug resistance: An update and perspective.. <b>2021</b> , 100796	17
141	Cancer Precision Drug Discovery Using Big Data and Artificial Intelligence Technologies. <b>2022</b> , 109-136	
140	MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis.. <b>2022</b> , 14,	0
139	Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer.. <b>2022</b> , 12, 869672	3
138	Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling.. <b>2022</b> ,	

- 137 Application of Pyrrolbenzodiazepines in Antibody Drug Conjugates. **2022**, 293-339 0
- 136 Endoscopic Applications of Near-Infrared Photoimmunotherapy (NIR-PIT) in Cancers of the Digestive and Respiratory Tracts.. **2022**, 10, 1
- 135 Long Term Survival in Patients with Metastatic Adenocarcinoma of the Lung in the Era of Targeted Agents. **2021**, 1, 41-54
- 134 Limited-Stage Small-Cell Lung Cancer: Current Progress and the Next Frontier. **2021**, 1, 317-333
- 133 Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice. **2021**, 17, 53 0
- 132 High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors.. **2021**, 11, 747692
- 131 Mutations in Squamous Cell Carcinomas of the Lung.. **2021**, 11, 788084 2
- 130 Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer. **2021**, 1-20 0
- 129 C1632 suppresses the migration and proliferation of non-small-cell lung cancer cells involving LIN28 and FGFR1 pathway.. **2021**, 1
- 128 Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy.. **2022**, 10, 1
- 127 EGFR signaling pathway as therapeutic target in human cancers.. **2022**, 1
- 126 Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.. **2022**, 237, 114381 0
- 125 Developing symptom management drugs. 314-324
- 124 DataSheet\_1.docx. **2020**,
- 123 Image\_1.tiff. **2020**,
- 122 DataSheet\_1.docx. **2020**,
- 121 Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care.. **2022**, 0
- 120 Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic. **2022**, 29, 3171-3186 1

119	A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies. <b>2022</b> , 12, 669	
118	Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686. <b>2022</b> , 114455	1
117	A Phase II, Single-Arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. <b>2022</b> ,	
116	Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.. <b>2022</b> , 22, 514	1
115	FBXW2 inhibits prostate cancer proliferation and metastasis via promoting EGFR ubiquitylation and degradation.. <b>2022</b> , 79, 268	0
114	Extracellular PKC $\beta$ signals to EGF receptor for tumor proliferation in liver cancer cells.. <b>2022</b> ,	1
113	Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment.. <b>2022</b> , 12, 1281	
112	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.. <b>2022</b> ,	2
111	Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study.. <b>2022</b> , 7, 100473	
110	Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors.. <b>2022</b> , 14,	0
109	Lung Cancer. <b>2022</b> , 259-283	
108	EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.. <b>2022</b> , 12, 8007	2
107	CPI Adult Cancer Imaging Special Edition Module. <b>2019</b> ,	
106	An Application of Quality by Design and Analytical Greenness Assessment Approach for the Development of Erlotinib Stability Indicating Method.	0
105	Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review. <b>2022</b> , 13,	1
104	Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC. 12,	0
103	Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras. <b>2022</b> , 65, 8416-8443	2
102	Clinical significance of epidermal growth factor receptor mutations in resected stage IA non-small cell lung cancer. <b>2022</b> , 55, 109	

101	Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients.	
100	Myths about diversity in clinical trials reduce return on investment for industry.	0
99	State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. <b>2022</b> , 23, 7037	0
98	A pharmacological exploration of targeted drug therapy in non-small cell lung cancer. <b>2022</b> , 39,	1
97	A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years.	
96	NNMT promotes the progression of intrahepatic cholangiocarcinoma by regulating aerobic glycolysis via the EGFR-STAT3 axis. <b>2022</b> , 11,	2
95	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. <b>2022</b> , 14, 3337	2
94	Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR. <b>2022</b> , 147, 105787	1
93	Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. <b>2015</b> , 44, 449-462	2
92	Immunotherapy in advanced NSCLC without driver mutations: available therapeutic alternatives after progression and future treatment options. <b>2022</b> ,	1
91	Placebo effect in the treatment of non-small cell lung cancer: a meta-analysis. Publish Ahead of Print,	
90	Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma. 12,	
89	Association of smoking with survival of patients with brain metastasis of lung cancer.	
88	Drug resistance in NSCLC is associated with tumor micro-environment. <b>2022</b> , 22, 100680	0
87	Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells. <b>2022</b> , 626, 156-166	
86	Chapter 21: Oncology: Rasburicase/G6PD Case. <b>2022</b> ,	0
85	Abbreviations. <b>2022</b> ,	0
84	Chapter 29: Pharmacogenomics in Ethical and Social Contexts. <b>2022</b> ,	0

83	Appendix 2: Glossary. <b>2022,</b>	o
82	Chapter 27: Rheumatology/Musculoskeletal Pain: Codeine/CYP2D6 Case. <b>2022,</b>	o
81	Chapter 8: Cardiology: Simvastatin/SLCO1B1 Case. <b>2022,</b>	o
80	Chapter 28: Information Resources for Pharmacogenomics. <b>2022,</b>	o
79	Chapter 18: Oncology: Somatic Disease and Pharmacogenomics. <b>2022,</b>	o
78	Chapter 17: Neurology: Fosphenytoin/Phenytoin/CYP2C9, HLA-B Case. <b>2022,</b>	o
77	Chapter 9: Cardiology: Warfarin/CYP2C9, VKORC1, CYP4F2 Case. <b>2022,</b>	o
76	Chapter 25: Rheumatology/Musculoskeletal Pain: Allopurinol/HLA-B Case. <b>2022,</b>	o
75	Chapter 12: Infectious Diseases: Abacavir/HLA-B Case. <b>2022,</b>	o
74	Chapter 15: Infectious Diseases: Gentamicin/MT-RNR1 Case. <b>2022,</b>	o
73	Pharmacogenomics: Foundations, Competencies, and the Pharmacistsâ Patient Care Process, 2nd Edition. <b>2022,</b>	o
72	Chapter 13: Infectious Diseases: Atazanavir/UGT1A1 Case. <b>2022,</b>	o
71	Chapter 30: Pharmacogenomics and Secondary/Incidental Findings. <b>2022,</b>	o
70	Chapter 16: Neurology: Carbamazepine/HLA-A, HLA-B Case. <b>2022,</b>	o
69	Dedication. <b>2022,</b>	o
68	Chapter 3: Pharmacogenomics Testing. <b>2022,</b>	o
67	An Immune-Related Genetic Feature Depicted the Heterogeneous Nature of Lung Adenocarcinoma and Squamous Cell Carcinoma and Their Distinctive Predicted Drug Responses. <b>2022,</b> 2022, 1-23	o
66	Chapter 24: Metabolic/Respiratory: Ivacaftor/CFTR Case. <b>2022,</b>	o

65	Chapter 23: Psychiatry: Paroxetine/CYP2D6 Case. <b>2022,</b>	○
64	Copyright. <b>2022,</b>	○
63	Chapter 2: Pharmacogenomics: Drug Exposure and Response. <b>2022,</b>	○
62	Chapter 22: Psychiatry: Amitriptyline/CYP2C19, CYP2D6 Case. <b>2022,</b>	○
61	Chapter 6: The Pharmacists' Patient Care Process (PPCP). <b>2022,</b>	○
60	Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. <b>2022, 29, 6260-6276</b>	○
59	Chapter 10: Endocrinology: Glipizide/G6PD Case. <b>2022,</b>	○
58	Chapter 1: Foundations of Pharmacogenomics. <b>2022,</b>	○
57	Chapter 20: Oncology: Capecitabine/DYPD Case. <b>2022,</b>	○
56	Preface. <b>2022,</b>	○
55	Chapter 14: Infectious Diseases: Voriconazole/CYP2C19 Case. <b>2022,</b>	○
54	Chapter 19: Oncology: Mercaptopurine/TPMT, NUDT15 Case. <b>2022,</b>	○
53	Chapter 7: Cardiology: Clopidogrel/CYP2C19 Case. <b>2022,</b>	○
52	Chapter 4: Pharmacists' Competencies in Genomics. <b>2022,</b>	○
51	Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer.	○
50	Appendix 1: Competency Connections. <b>2022,</b>	○
49	Chapter 5: Implementation of Pharmacogenomics across Practice Settings. <b>2022,</b>	○
48	Chapter 26: Rheumatology/Musculoskeletal Pain: Azathioprine/TPMT, NUDT15; Celecoxib/CYP2C9 Case. <b>2022,</b>	○



47	Chapter 11: Immunology: Tacrolimus/CYP3A5 Case. <b>2022,</b>	0
46	The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab. <b>2022, 14, 4598</b>	0
45	Immune Effect of T Lymphocytes Infiltrated by Tumors on Non-Small-Cell Lung Cancer. <b>2022, 2022, 1-10</b>	0
44	SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition. <b>2022, 2022, 1-14</b>	0
43	One-Pot Multicomponent Reaction: A Highly Versatile Strategy for the Construction of Valuable Nitrogen-Containing Heterocycles. <b>2022, 7,</b>	0
42	A perspective study on the RTK, PI3K, B-Raf, CDK and the multi-protein targeting in medicinal chemistry.	0
41	The Management of Oligometastases in Non-small Cell Lung Cancer – Is Stereotactic Ablative Radiotherapy now Standard of Care?. <b>2022,</b>	0
40	Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1. <b>2022, 8,</b>	1
39	Mechanisms of Drug Hypersensitivity. <b>2022, 35-52</b>	0
38	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <b>2022, 15,</b>	1
37	Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.	1
36	Deciphering the Impact of HER2 Alterations on Non-Small-Cell Lung Cancer: From Biological Mechanisms to Therapeutic Approaches. <b>2022, 12, 1651</b>	0
35	Algorithme thérapeutique des CBNPC sans mutation addictive. <b>2022, 14, 2S165-2S177</b>	0
34	Squamous cell lung cancer: Current landscape and future therapeutic options. <b>2022,</b>	0
33	Principles of Medical Oncology. 1-13	0
32	Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches. <b>2022, 19, 14324</b>	0
31	A Beclin 1-targeting stapled peptide synergizes with erlotinib to potently inhibit proliferation of non-small-cell lung cancer cells. <b>2022, 636, 125-131</b>	1
30	Improved Survival of Advanced Lung Cancer in Singapore Over the Past Decade. <b>2017, 46, 333-338</b>	3

- 29 Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. **2022**, ○
- 28 Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. **2022**, 7, 100605 ○
- 27 Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer. **2023**, 80, 129084 ○
- 26 Topical Zhiyang Pingfu Liquid for Moderate to Severe Skin Rash Associated With EGFRIs: A double-blinded randomized controlled trial. **2022**, 21, 153473542211404 ○
- 25 Cell-Surface Receptors: EGFR- and VEGFR-Targeted Agents. **2022**, 153-172 ○
- 24 Design, synthesis and biological evaluation of novel 3,4-dihydro-2H-[1,4]oxazino [2,3-f]quinazolin derivatives as EGFR-TKIs. **2023**, 80, 129104 ○
- 23 Reversible Drug Resistance Mechanisms in Non-small Cell Lung Cancer. **2022**, 142, 1321-1326 ○
- 22 Tarsoconjunctival Granulation Tissue Formation Associated with EGFR Inhibitors. ○
- 21 Lung Cancer: Recent Advances. **2010**, 39, 819-821 ○
- 20 Tumour Genetics and Genomics to Personalise Cancer Treatment. **2011**, 40, 362-368 ○
- 19 The Therapeutic Application of RBAC in Cancer. **2023**, 67-79 ○
- 18 Tryptophan stress activates EGFR-RAS-signaling to MTORC1 and p38/MAPK to sustain translation and AHR-dependent autophagy. ○
- 17 ANALYSIS OF POSTOPERATIVE COMPLICATIONS IN THE TREATMENT OF PATIENTS WITH LUNG CANCER. **2022**, 112-117 ○
- 16 Historical development of EGFR-targeted therapy. **2023**, 1-11 ○
- 15 Radical Radiotherapy in Stage I Non-small Cell Lung Cancer (NSCLC) – Singapore National Cancer Centre Experience. **2007**, 36, 778-783 ○
- 14 Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. **2023**, 15, 629 ○
- 13 The development and implementation of EGFR inhibitors in advanced NSCLC. **2023**, 13-36 ○
- 12 SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer. **2023**, 11, e006055 ○

- 11 The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases. 13,
- 10 Uncommon EGFR-Mutant NSCLC One Drug Does Not Fit All. **2023**, 4, 100477
- 9 Real-World Data on EGFR and ALK Testing and TKI Usage in Norway A Nation-Wide Population Study. **2023**, 15, 1505
- 8 A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. **2023**, 8, 101183
- 7 Association of smoking with the survival of patients with brain metastasis of lung cancer. 14,
- 6 The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. **2023**, 1-32
- 5 Determination of pKa Values for Some Tyrosine Kinase Inhibitors Using the Reversed-Phase Liquid Chromatography.
- 4 Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study. **2023**, 28, 3014
- 3 Feasibility and safety of shortened hypofractionated high-dose palliative lung radiotherapy A retrospective planning study. **2023**, 108, 102559
- 2 Targeted therapy. **2023**, 205-411
- 1 Rare tumors: a blue ocean of investigation.